{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:59:51Z","timestamp":1792504791514,"version":"4.5.0"},"reference-count":686,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.4158\/ep171764.appgl","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T17:16:14Z","timestamp":1493054174000},"page":"1-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":822,"special_numbering":"S2","title":["American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease"],"prefix":"10.1016","volume":"23","author":[{"given":"Paul S.","family":"Jellinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Rosenblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Bloomgarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grunberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris K.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.H.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Mechanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pessah-Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Wyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Jellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.H.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Bloomgarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grunberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris K.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Mechanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pessah-Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Rosenblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Wyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Zangeneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.H.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Bloomgarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grunberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris K.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Jellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Rosenblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Wyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP171764.APPGL_bb0005","first-page":"e38","article-title":"Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-2004-835377","article-title":"The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol","volume":"4","author":"Nicholls","year":"2004","journal-title":"Semin Vasc Med."},{"key":"10.4158\/EP171764.APPGL_bb0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.atherosclerosis.2008.07.028","article-title":"Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: The Edinburgh Artery Study","volume":"203","author":"Wild","year":"2009","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/STROKEAHA.108.523035","article-title":"Metabolic syndrome clusters and the risk of incident stroke: the atherosclerosis risk in communities (ARIC) study","volume":"40","author":"Rodriguez-Colon","year":"2009","journal-title":"Stroke."},{"key":"10.4158\/EP171764.APPGL_bb0025","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.amjcard.2010.05.030","article-title":"30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. (Erratum in: Am J Cardiol. 2010;106:1826)","volume":"106","author":"Cohen","year":"2010","journal-title":"Am J Cardiol."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.18.S1.1","article-title":"American Association of Clinical Endocrinologists\u2019 guidelines for management of dyslipidemia and prevention of atherosclerosis","volume":"18","author":"Jellinger","year":"2012","journal-title":"Endocr Pract."},{"issue":"Suppl 2","key":"10.4158\/EP171764.APPGL_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.17.S2.1","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan","volume":"17","author":"Handelsman","year":"2011","journal-title":"Endocr Pract."},{"key":"10.4158\/EP171764.APPGL_bb0040","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","volume":"269","year":"1993","journal-title":"JAMA"},{"issue":"7","key":"10.4158\/EP171764.APPGL_bb0045","doi-asserted-by":"crossref","first-page":"692","DOI":"10.4158\/EP14166.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Protocol for Standardized Production of Clinical Practice Guidelines, Algorithms, and Checklists - 2014 Update and the AACe G4G Program","volume":"20","author":"Mechanick","year":"2014","journal-title":"Endocr Pract."},{"key":"10.4158\/EP171764.APPGL_bb0050","article-title":"National Institutes of Health; National Heart Lung, and Blood Institute; 2002 National Cholesterol Education Program","author":"Brunzell","year":"2002","journal-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final Report"},{"key":"10.4158\/EP171764.APPGL_bb0055","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb0060","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0065","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archinte.1992.00400190110021","article-title":"Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group","volume":"152","author":"Neaton","year":"1992","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0070","first-page":"1876","article-title":"Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction","volume":"97","author":"Grundy","year":"1998","journal-title":"American Heart Association. Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4158\/EP.9.S2.5","article-title":"American College of Endocrinology position statement on the insulin resistance syndrome","volume":"9","author":"Einhorn","year":"2003","journal-title":"Endocr Pract."},{"key":"10.4158\/EP171764.APPGL_bb0080","year":"2004","journal-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure"},{"key":"10.4158\/EP171764.APPGL_bb0085","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","article-title":"Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies","volume":"15","author":"Weiner","year":"2004","journal-title":"J Am Soc Nephrol."},{"key":"10.4158\/EP171764.APPGL_bb0090","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb0095","first-page":"126","article-title":"American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome","volume":"11","year":"2005","journal-title":"Endocr Pract."},{"key":"10.4158\/EP171764.APPGL_bb0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jacl.2007.10.001","article-title":"LDL Particle number and risk of future cardiovascular disease in the Framingham offspring study implications for LDL management","volume":"1","author":"Cromwell","year":"2007","journal-title":"J Clin Lipidol."},{"key":"10.4158\/EP171764.APPGL_bb0105","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb0110","first-page":"S1","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171764.APPGL_bb0115","doi-asserted-by":"crossref","first-page":"4A40S","DOI":"10.1016\/S0002-9343(96)00319-1","article-title":"Lipid management: current diet and drug treatment options","volume":"101","author":"Stone","year":"1996","journal-title":"Am J Med"},{"key":"10.4158\/EP171764.APPGL_bb0120","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/cs1010671","article-title":"United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)","volume":"101","author":"Stevens","year":"2001","journal-title":"Clin Sci"},{"key":"10.4158\/EP171764.APPGL_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb0130","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb0135","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.amjcard.2004.03.023","article-title":"Framingham and risk score prediction of lifetime risk for coronary heart disease","volume":"94","author":"Lloyd-Jones","year":"2004","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0150","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","article-title":"Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg\/dl and C-reactive protein <2 mg\/l: an analysis of the PROVE-IT TIMI-22 trial","volume":"45","author":"Ridker","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0155","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0160","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. (Erratum in: Circulation. 2006;113:e847.)","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.4158\/EP171764.APPGL_bb0165","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0170","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0175","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb0180","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jacc.2015.08.035","volume":"66","author":"McClelland","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0185","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000114834.85476.81","article-title":"Evidence-based guidelines for cardiovascular disease prevention in women","volume":"109","author":"Mosca","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0190","article-title":"Hard Coronary Heart Disease (10 Year Risk)","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb0195","article-title":"MESA 10-Year CHD Risk with Coronary Artery Calcification","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb0200","article-title":"Reynolds Risk Score: Calculating Heart and Stroke Risk for Women and Men","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb0205","article-title":"UKPDS Risk Engine University of Oxford Diabetes Trial Unit, The Oxford Centre for Diabetes, Endocrinology and Metabolism","year":"2016"},{"issue":"3 Suppl 1","key":"10.4158\/EP171764.APPGL_bb0210","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2007.01.002","article-title":"Multiple risk factors for cardiovascular disease and diabetes mellitus","volume":"120","author":"Smith","year":"2007","journal-title":"Am J Med."},{"key":"10.4158\/EP171764.APPGL_bb0215","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1161\/01.STR.0000141417.66620.09","article-title":"The relative impact of inadequate primary and secondary prevention on cardiovascular mortality in the United States","volume":"35","author":"Qureshi","year":"2004","journal-title":"Stroke."},{"key":"10.4158\/EP171764.APPGL_bb0220","first-page":"1","article-title":"Lipid management: past, present, and future","volume":"77A","author":"Betteridge","year":"1996","journal-title":"Br J Clin Pract Suppl."},{"key":"10.4158\/EP171764.APPGL_bb0225","first-page":"237","article-title":"New and classical risk factors--the M\u00fcnster heart study (PROCAM)","volume":"2","author":"Assmann","year":"1997","journal-title":"Eur J Med Res."},{"key":"10.4158\/EP171764.APPGL_bb0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF02892285","article-title":"Diet and cardiovascular disease prevention: what works?","volume":"19","author":"Van Horn","year":"1997","journal-title":"Ann Behav Med."},{"issue":"Suppl A","key":"10.4158\/EP171764.APPGL_bb0235","first-page":"A2","article-title":"The M\u00fcnster Heart Study (PROCAM). Results of follow-up at 8 years","volume":"19","author":"Assmann","year":"1998","journal-title":"Eur Heart J"},{"key":"10.4158\/EP171764.APPGL_bb0240","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0735-1097(98)00522-1","article-title":"Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events","volume":"33","author":"Pfeffer","year":"1999","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0245","first-page":"1383","article-title":"Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb0250","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.4158\/EP171764.APPGL_bb0255","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb0260","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. (Erratum in: JAMA. 2005;28:3092)","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.4158\/EP171764.APPGL_bb0265","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0270","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2006.07.041","article-title":"Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study","volume":"48","author":"Waters","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0275","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/CIRCOUTCOMES.109.848473","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"10.4158\/EP171764.APPGL_bb0280","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long- Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0285","first-page":"436","article-title":"How do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control?","volume":"8","author":"Zimmerman","year":"2015","journal-title":"Am Health Drug Benefits."},{"key":"10.4158\/EP171764.APPGL_bb0290","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1161\/01.CIR.69.6.1065","article-title":"Family history of heart attack as an independent predictor of death due to cardiovascular disease","volume":"69","author":"Barrett-Connor","year":"1984","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0295","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0735-1097(84)80408-8","article-title":"Family history as an independent risk factor for coronary artery disease","volume":"4","author":"Shea","year":"1984","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0300","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/hc2901.093115","article-title":"Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women","volume":"104","author":"Sesso","year":"2001","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0305","doi-asserted-by":"crossref","first-page":"34Q","DOI":"10.1016\/S0002-9149(98)00771-1","article-title":"Did grandma give you heart disease? The new battle against coronary artery disease","volume":"82","author":"Superko","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0310","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.hjr.0000129744.61087.b4","article-title":"Parental history of stroke and myocardial infarction predicts coronary artery calcification: The Coronary Artery Risk Development in Young Adults (CARDIA) study","volume":"11","author":"Fornage","year":"2004","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"10.4158\/EP171764.APPGL_bb0315","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1161\/01.CIR.0000144464.11080.14","article-title":"Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history","volume":"110","author":"Nasir","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0320","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1161\/01.ATV.0000222012.56447.00","article-title":"Young adults with family history of coronary heart disease have increased arterial vulnerability to metabolic risk factors: the Cardiovascular Risk in Young Finns Study","volume":"26","author":"Juonala","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb0325","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"1981","article-title":"Familial hypercholesterolemia","author":"Goldstein","year":"1995"},{"key":"10.4158\/EP171764.APPGL_bb0330","first-page":"169","article-title":"Familial hypercholesterolemia","volume":"33","author":"Bouhairie","year":"2015","journal-title":"Cardiol Clin."},{"key":"10.4158\/EP171764.APPGL_bb0335","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MOL.0000000000000325","article-title":"Diagnostic scoring for familial hypercholesterolaemia in practice","volume":"27","author":"Haralambos","year":"2016","journal-title":"Curr Opin Lipidol."},{"key":"10.4158\/EP171764.APPGL_bb0340","first-page":"32","article-title":"Familial hypercholesterolemia: Review of diagnosis, screening, and treatment","volume":"62","author":"Turgeon","year":"2016","journal-title":"Can Fam Physician."},{"key":"10.4158\/EP171764.APPGL_bb0345","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/cpt.281","article-title":"Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids","volume":"99","author":"Shantha","year":"2016","journal-title":"Clin Pharmacol Ther."},{"key":"10.4158\/EP171764.APPGL_bb0350","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb0355","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb0360","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP151126.CS","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm--2016 Executive Summary","volume":"22","author":"Garber","year":"2016","journal-title":"Endocr Pract."},{"key":"10.4158\/EP171764.APPGL_bb0365","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/1047-2797(92)90033-M","article-title":"Lipids and risk of coronary heart disease","volume":"2","author":"Castelli","year":"1992","journal-title":"The Framingham Study. Ann Epidemiol."},{"key":"10.4158\/EP171764.APPGL_bb0370","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-121-9-199411010-00002","article-title":"Cholesterol and coronary heart disease: predicting risks by levels and ratios","volume":"121","author":"Kinosian","year":"1994","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0375","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0749-3797(03)00092-8","article-title":"Cholesterol measures to identify and treat individuals at risk for coronary heart disease","volume":"25","author":"Natarajan","year":"2003","journal-title":"Am J Prev Med."},{"key":"10.4158\/EP171764.APPGL_bb0380","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb0385","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","article-title":"Use of metabolic markers to identify overweight individuals who are insulin resistant","volume":"139","author":"McLaughlin","year":"2003","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0390","first-page":"1083","article-title":"AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission","volume":"37","author":"Gualandri","year":"1985","journal-title":"Am J Hum Genet."},{"key":"10.4158\/EP171764.APPGL_bb0395","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/01.CIR.103.15.1949","article-title":"Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study","volume":"103","author":"Sirtori","year":"2001","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0400","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0033-0620(98)80007-8","article-title":"Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors","volume":"41","author":"Rubenfire","year":"1998","journal-title":"Prog Cardiovasc Dis."},{"key":"10.4158\/EP171764.APPGL_bb0405","first-page":"737","article-title":"High density lipoprotein cholesterol and mortality","volume":"8","author":"Wilson","year":"1988","journal-title":"The Framingham Heart Study. Arteriosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb0410","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0415","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0420","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0021-9150(93)90183-U","article-title":"Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase","volume":"104","author":"Mackness","year":"1993","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb0425","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archinte.159.10.1049","article-title":"New perspectives on the management of low levels of high-density lipoprotein cholesterol","volume":"159","author":"Harper","year":"1999","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0430","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0026-0495(89)90113-3","article-title":"Plasma lipoproteins in healthy octogenarians: lack of reduced high density lipoprotein cholesterol levels: results from the Framingham Heart Study","volume":"38","author":"Schaefer","year":"1989","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb0435","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ageing\/19.2.119","article-title":"High-density lipoprotein cholesterol and longevity","volume":"19","author":"Nikkil\u00e4","year":"1990","journal-title":"Age Ageing."},{"key":"10.4158\/EP171764.APPGL_bb0440","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/BF01744268","article-title":"Elevated high-density-lipoprotein cholesterol and normal triglycerides as markers of longevity","volume":"69","author":"Nikkil\u00e4","year":"1991","journal-title":"Klin Wochenschr."},{"key":"10.4158\/EP171764.APPGL_bb0445","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosissup.2004.03.003","article-title":"HDL: a recipe for longevity","volume":"5","author":"Barter","year":"2004","journal-title":"Atheroscler Suppl."},{"key":"10.4158\/EP171764.APPGL_bb0450","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/archinte.159.10.1038","article-title":"Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives","volume":"159","author":"Gotto","year":"1999","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0455","year":"1995","journal-title":"National Diabetes Data Group. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America, 2nd Edition"},{"key":"10.4158\/EP171764.APPGL_bb0460","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/diacare.21.1.160","article-title":"Management of dyslipidemia in adults with diabetes","volume":"21","author":"Haffner","year":"1998","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb0465","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb0470","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","author":"Di Angelantonio","year":"2015","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0475","first-page":"14","article-title":"Dyslipidaemia and coagulation defects of insulin resistance","author":"Frohlich","year":"2000","journal-title":"Int J Clin Pract Suppl."},{"key":"10.4158\/EP171764.APPGL_bb0480","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","article-title":"Diabetes, hypertension, and cardiovascular disease: an update. (Erratum in: Hypertension. 2001;37:1350)","volume":"37","author":"Sowers","year":"2001","journal-title":"Hypertension"},{"key":"10.4158\/EP171764.APPGL_bb0485","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2337\/diabetes.51.4.1157","article-title":"Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death","volume":"51","author":"Stehouwer","year":"2002","journal-title":"Diabetes."},{"key":"10.4158\/EP171764.APPGL_bb0490","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1464-5491.2005.01562.x","article-title":"Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy","volume":"22","author":"Targher","year":"2005","journal-title":"Diabet Med."},{"key":"10.4158\/EP171764.APPGL_bb0495","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11892-007-0035-1","article-title":"Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation","volume":"7","author":"Boden","year":"2007","journal-title":"Curr Diab Rep."},{"key":"10.4158\/EP171764.APPGL_bb0500","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4158\/EP.14.7.933","article-title":"Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists","volume":"14","author":"Garber","year":"2008","journal-title":"Endocr Pract."},{"key":"10.4158\/EP171764.APPGL_bb0505","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/01.ATV.19.4.1014","article-title":"Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy","volume":"19","author":"Lehto","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb0510","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb0515","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/db05-1423","article-title":"The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience","volume":"55","author":"Pambianco","year":"2006","journal-title":"Diabetes."},{"key":"10.4158\/EP171764.APPGL_bb0520","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/archinternmed.2009.193","volume":"169","author":"Nathan","year":"2009","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0525","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.2337\/db10-0862","article-title":"Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes","volume":"59","author":"Secrest","year":"2010","journal-title":"Diabetes."},{"key":"10.4158\/EP171764.APPGL_bb0530","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.2337\/dc14-1720","article-title":"Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association","volume":"37","author":"de Ferranti","year":"2014","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb0535","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.2337\/diab.27.11.1078","article-title":"Serum lipids and lipoproteins in insulin-treated diabetes. Demonstration of increased high density lipoprotein concentrations","volume":"27","author":"Nikkil\u00e4","year":"1978","journal-title":"Diabetes."},{"issue":"Suppl 2","key":"10.4158\/EP171764.APPGL_bb0540","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2337\/diab.41.2.S12","article-title":"Quantitative and qualitative abnormalities in diabetes mellitus","volume":"41","author":"Taskinen","year":"1992","journal-title":"Diabetes."},{"key":"10.4158\/EP171764.APPGL_bb0545","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0002-8703(91)90513-H","article-title":"Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus","volume":"122","author":"Valsania","year":"1991","journal-title":"Am Heart J."},{"key":"10.4158\/EP171764.APPGL_bb0550","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2337\/diacare.20.5.704","article-title":"The impact of diabetes on survival among patients with first myocardial infarction","volume":"20","author":"Chun","year":"1997","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb0555","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0735-1097(97)00342-2","article-title":"Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation","volume":"30","author":"Rozenman","year":"1997","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0560","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/diacare.21.1.69","article-title":"Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group","volume":"21","author":"Miettinen","year":"1998","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb0565","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0002-9149(88)91199-X","article-title":"Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor","volume":"62","author":"Savage","year":"1988","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0570","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.2337\/diabetes.52.11.2833","article-title":"Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. (Erratum in: Diabetes. 2004;53:2177)","volume":"52","author":"Dabelea","year":"2003","journal-title":"Diabetes"},{"key":"10.4158\/EP171764.APPGL_bb0575","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1161\/CIRCULATIONAHA.104.529651","article-title":"Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus","volume":"111","author":"Libby","year":"2005","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0580","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/ije\/27.6.976","article-title":"Cardiovascular disease in insulin dependent diabetes mellitus: similar rates but different risk factors in the US compared with Europe","volume":"27","author":"Orchard","year":"1998","journal-title":"Int J Epidemiol."},{"key":"10.4158\/EP171764.APPGL_bb0585","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1136\/bmj.294.6588.1651","article-title":"Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus","volume":"294","author":"Borch-Johnsen","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.4158\/EP171764.APPGL_bb0590","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1001\/jama.290.16.2159","volume":"290","year":"2003","journal-title":"JAMA"},{"key":"10.4158\/EP171764.APPGL_bb0595","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2337\/diabetes.52.5.1210","article-title":"Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older","volume":"52","author":"Alexander","year":"2003","journal-title":"Diabetes"},{"key":"10.4158\/EP171764.APPGL_bb0600","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.atherosclerosis.2005.07.028","article-title":"High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease","volume":"186","author":"Mackness","year":"2006","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb0605","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP15672.GLSUPPL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr Pract."},{"key":"10.4158\/EP171764.APPGL_bb0615","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.CIR.89.3.1333","article-title":"Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)","volume":"89","author":"Program","year":"1994","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0620","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/bmj.317.7152.167","article-title":"Survival in treated hypertension: follow up study after two decades","volume":"317","author":"Andersson","year":"1998","journal-title":"BMJ."},{"key":"10.4158\/EP171764.APPGL_bb0625","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/00004872-200018070-00003","article-title":"Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women","volume":"18","author":"Nanchahal","year":"2000","journal-title":"J Hypertens."},{"key":"10.4158\/EP171764.APPGL_bb0630","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2796.2005.01497.x","article-title":"Stroke and coronary heart disease in treated hypertension - a prospective cohort study over three decades","volume":"257","author":"Almgren","year":"2005","journal-title":"J Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0635","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(07)61538-4","article-title":"Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study","volume":"370","author":"Boggia","year":"2007","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb0640","first-page":"1","year":"1996"},{"key":"10.4158\/EP171764.APPGL_bb0645","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1365-2362.1993.tb00724.x","article-title":"Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution","volume":"23","author":"Freeman","year":"1993","journal-title":"Eur J Clin Invest."},{"key":"10.4158\/EP171764.APPGL_bb0650","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2796.1995.tb00869.x","article-title":"Lipid intolerance in smokers","volume":"237","author":"Axelsen","year":"1995","journal-title":"J Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0655","first-page":"503","article-title":"Smoking habits and lipoproteins in British women","volume":"88","author":"Razay","year":"1995","journal-title":"QJM."},{"key":"10.4158\/EP171764.APPGL_bb0660","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1053\/euhj.1998.1086","article-title":"Smoking, lipoproteins and coronary heart disease risk. Data from the M\u00fcnster Heart Study (PROCAM)","volume":"19","author":"Cullen","year":"1998","journal-title":"Eur Heart J."},{"key":"10.4158\/EP171764.APPGL_bb0665","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0022-2275(20)32531-1","article-title":"Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activities","volume":"39","author":"Mero","year":"1998","journal-title":"J Lipid Res."},{"key":"10.4158\/EP171764.APPGL_bb0670","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s102380200011","article-title":"Relationship between smoking habits and low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, and triglycerides in a hypercholesterolemic adult cohort, in relation to gender and age","volume":"2","author":"Schuitemaker","year":"2002","journal-title":"Clin Exp Med."},{"key":"10.4158\/EP171764.APPGL_bb0675","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0091-7435(03)00110-5","article-title":"The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis","volume":"37","author":"Maeda","year":"2003","journal-title":"Prev Med."},{"key":"10.4158\/EP171764.APPGL_bb0680","series-title":"Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults","author":"NHLBI","year":"1998"},{"key":"10.4158\/EP171764.APPGL_bb0685","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","article-title":"Prevalence of overweight and obesity in the United States, 1999-2004","volume":"295","author":"Ogden","year":"2006","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0690","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.ATV.16.12.1509","article-title":"Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study","volume":"16","author":"Lamon-Fava","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb0695","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/01.HYP.0000184282.51550.00","article-title":"Cardiovascular mortality in overweight subjects: the key role of associated risk factors","volume":"46","author":"Thomas","year":"2005","journal-title":"Hypertension."},{"key":"10.4158\/EP171764.APPGL_bb0700","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.metabol.2006.10.016","article-title":"Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study","volume":"56","author":"Onat","year":"2007","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb0705","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.atherosclerosis.2006.03.012","article-title":"Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study","volume":"191","author":"Onat","year":"2007","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb0710","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/diabetes.52.1.172","article-title":"The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat","volume":"52","author":"Nieves","year":"2003","journal-title":"Diabetes."},{"key":"10.4158\/EP171764.APPGL_bb0715","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2337\/diabetes.53.8.2087","article-title":"Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome","volume":"53","author":"Carr","year":"2004","journal-title":"Diabetes."},{"key":"10.4158\/EP171764.APPGL_bb0725","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/01.ATV.11.2.298","article-title":"Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects","volume":"11","author":"de Graaf","year":"1991","journal-title":"Arterioscler Thromb."},{"key":"10.4158\/EP171764.APPGL_bb0730","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0021-9150(92)90255-F","article-title":"Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size","volume":"93","author":"Tribble","year":"1992","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb0735","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0002-9343(93)90144-E","article-title":"Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B","volume":"94","author":"Chait","year":"1993","journal-title":"Am J Med."},{"key":"10.4158\/EP171764.APPGL_bb0740","doi-asserted-by":"crossref","first-page":"3Q","DOI":"10.1016\/S0002-9149(98)00769-3","article-title":"Low-density lipoproteins and risk for coronary artery disease","volume":"82","author":"Ballantyne","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0745","doi-asserted-by":"crossref","first-page":"58S","DOI":"10.1016\/S0002-9343(98)00213-7","article-title":"Triglycerides and atherogenic lipoproteins: rationale for lipid management","volume":"105","author":"Krauss","year":"1998","journal-title":"Am J Med."},{"key":"10.4158\/EP171764.APPGL_bb0750","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","article-title":"Lipids and lipoproteins in patients with type 2 diabetes","volume":"27","author":"Krauss","year":"2004","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb0755","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1001\/jama.1988.03410130125037","article-title":"Low-density lipoprotein sub-class patterns and risk of myocardial infarction","volume":"260","author":"Austin","year":"1988","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0760","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/jama.1996.03540110029028","article-title":"Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women","volume":"276","author":"Gardner","year":"1996","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0765","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.ATV.0000053385.64132.2D","article-title":"Smallest LDL particles are most strongly related to coronary disease progression in men","volume":"23","author":"Williams","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb0770","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1161\/01.ATV.0000022015.97341.3A","article-title":"Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study","volume":"22","author":"Kuller","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb0775","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2006.05.007","article-title":"LDL particle sub-classes, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"192","author":"Mora","year":"2007","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb0780","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/01.CIR.82.2.495","article-title":"Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk","volume":"82","author":"Austin","year":"1990","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0785","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2265.2001.01228.x","article-title":"Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters","volume":"54","author":"Pirwany","year":"2001","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP171764.APPGL_bb0790","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","article-title":"Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance","volume":"52","author":"Garvey","year":"2003","journal-title":"Diabetes."},{"key":"10.4158\/EP171764.APPGL_bb0795","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.metabol.2004.09.002","article-title":"Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study","volume":"54","author":"Goff","year":"2005","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb0800","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0002-8703(86)90296-6","article-title":"The triglyceride issue: a view from Framingham","volume":"112","author":"Castelli","year":"1986","journal-title":"Am Heart J."},{"key":"10.4158\/EP171764.APPGL_bb0805","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jama.1996.03540110036029","article-title":"A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction","volume":"276","author":"Stampfer","year":"1996","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0810","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/archinte.1997.00440300051004","article-title":"Triglycerides and coronary risk in women and the elderly","volume":"157","author":"LaRosa","year":"1997","journal-title":"Arch Intern Med."},{"issue":"Suppl M","key":"10.4158\/EP171764.APPGL_bb0815","first-page":"M8","article-title":"The emergence of triglycerides as a significant independent risk factor in coronary artery disease","volume":"19","author":"Assmann","year":"1998","journal-title":"Eur Heart J"},{"key":"10.4158\/EP171764.APPGL_bb0820","doi-asserted-by":"crossref","first-page":"7B","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0825","first-page":"1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"(Erratum in: Circulation. 1998;97:1995). Circulation"},{"key":"10.4158\/EP171764.APPGL_bb0830","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijcard.2005.06.056","article-title":"Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome","volume":"108","author":"Onat","year":"2006","journal-title":"Int J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0835","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/hrt.2006.095554","article-title":"Triglyceride level is associated with wave reflections and arterial stiffness in apparently healthy middle-aged men","volume":"93","author":"Aznaouridis","year":"2007","journal-title":"Heart."},{"key":"10.4158\/EP171764.APPGL_bb0840","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0845","doi-asserted-by":"crossref","first-page":"1B","DOI":"10.1016\/S0002-9149(98)00030-7","article-title":"Consensus statement: Role of therapy with \u201cstatins\u201d in patients with hypertriglyceridemia","volume":"81","author":"Grundy","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0850","doi-asserted-by":"crossref","first-page":"25F","DOI":"10.1016\/S0002-9149(99)00211-8","article-title":"Hypertriglyceridemia, insulin resistance, and the metabolic syndrome","volume":"83","author":"Grundy","year":"1999","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0855","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-90-1-85","article-title":"Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study","volume":"90","author":"Kannel","year":"1979","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb0860","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0002-9149(92)90550-I","article-title":"Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular M\u00fcnster study","volume":"70","author":"Assmann","year":"1992","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0865","doi-asserted-by":"crossref","first-page":"22Q","DOI":"10.1016\/S0002-9149(98)00770-X","article-title":"Triglyceride as a risk factor for coronary artery disease","volume":"82","author":"Gotto","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb0870","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0875","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0880","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s001250050700","article-title":"Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM","volume":"40","author":"Malmstrom","year":"1997","journal-title":"Diabetologia."},{"key":"10.4158\/EP171764.APPGL_bb0885","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0022-2275(20)34298-X","article-title":"Aortic accumulation and plasma clearance of beta-VLDL and HDL: effects of diet-induced hypercholesterolemia in rabbits","volume":"26","author":"Daugherty","year":"1985","journal-title":"J Lipid Res."},{"key":"10.4158\/EP171764.APPGL_bb0890","first-page":"172","article-title":"Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus","volume":"76","author":"Chen","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP171764.APPGL_bb0895","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.ATV.14.11.1767","article-title":"Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque","volume":"14","author":"Rapp","year":"1994","journal-title":"Arterioscler Thromb."},{"key":"10.4158\/EP171764.APPGL_bb0900","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/01.ATV.18.3.441","article-title":"Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1","volume":"18","author":"Ginsberg","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb0905","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2362.1998.00317.x","article-title":"Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall--evidence that plaque cholesterol may be derived from post-prandial lipoproteins","volume":"28","author":"Proctor","year":"1998","journal-title":"Eur J Clin Invest."},{"key":"10.4158\/EP171764.APPGL_bb0910","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2174\/0929867054546609","article-title":"Clinical relevance of postprandial lipaemia","volume":"12","author":"Kolovou","year":"2005","journal-title":"Curr Med Chem."},{"key":"10.4158\/EP171764.APPGL_bb0915","article-title":"HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease","author":"Laufs","year":"2011","journal-title":"Program of the European Society of Cardiology Congress"},{"key":"10.4158\/EP171764.APPGL_bb0920","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0026-0495(03)00104-5","article-title":"Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome","volume":"52","author":"Glueck","year":"2003","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb0925","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1210\/jc.2003-030334","article-title":"Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome","volume":"88","author":"Christian","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP171764.APPGL_bb0930","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1210\/jc.2003-032237","article-title":"Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome","volume":"89","author":"Talbott","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP171764.APPGL_bb0935","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3109\/00016349209006227","article-title":"Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women","volume":"71","author":"Dahlgren","year":"1992","journal-title":"Acta Obstet Gynecol Scand."},{"key":"10.4158\/EP171764.APPGL_bb0940","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0015-0282(16)54892-4","article-title":"Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones","volume":"57","author":"Dahlgren","year":"1992","journal-title":"Fertil Steril."},{"key":"10.4158\/EP171764.APPGL_bb0945","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/humrep\/15.4.785","article-title":"Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome","volume":"15","author":"Cibula","year":"2000","journal-title":"Hum Reprod."},{"key":"10.4158\/EP171764.APPGL_bb0950","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1001\/jama.1992.03480240088040","article-title":"Lipoprotein(a). A genetic risk factor for premature coronary heart disease","volume":"267","author":"Scanu","year":"1992","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0955","first-page":"57U","article-title":"Lipoprotein(a) as a risk factor for coronary artery disease","volume":"82","author":"Marcovina","year":"1998","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0960","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.1993.03510180065035","article-title":"A prospective study of lipoprotein(a) and the risk of myocardial infarction","volume":"270","author":"Ridker","year":"1993","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0965","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jama.1994.03510370051031","article-title":"Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial","volume":"271","author":"Schaefer","year":"1994","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0970","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.1995.03520400039041","article-title":"Plasma concentration of lipoprotein(a) and the risk of future stroke","volume":"273","author":"Ridker","year":"1995","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb0975","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0980","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb0985","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0021-9150(02)00026-6","article-title":"Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study","volume":"163","author":"Luc","year":"2002","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb0990","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/heart.89.8.893","article-title":"Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia","volume":"89","author":"van Wissen","year":"2003","journal-title":"Heart."},{"key":"10.4158\/EP171764.APPGL_bb0995","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2004.12.015","article-title":"PROSPER Study Group Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER)","volume":"180","author":"Gaw","year":"2005","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb1000","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.296.11.1363","article-title":"Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women","volume":"296","author":"Suk Danik","year":"2006","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/01.ATV.13.7.1037","article-title":"Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans","volume":"13","author":"Marcovina","year":"1993","journal-title":"The CARDIA study. Arterioscler Thromb."},{"key":"10.4158\/EP171764.APPGL_bb1010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1399-0004.1997.tb04342.x","article-title":"Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study","volume":"52","author":"Berg","year":"1997","journal-title":"Clin Genet."},{"key":"10.4158\/EP171764.APPGL_bb1015","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/sj.ijo.0802778","article-title":"Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1","volume":"28","author":"Skurk","year":"2004","journal-title":"Int J Obes Relat Metab Disord."},{"key":"10.4158\/EP171764.APPGL_bb1020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2005-871741","article-title":"Visceral fat as a determinant of fibrinolysis and hemostasis","volume":"5","author":"Mertens","year":"2005","journal-title":"Semin Vasc Med."},{"key":"10.4158\/EP171764.APPGL_bb1025","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1161\/CIRCULATIONAHA.105.557132","article-title":"Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke?","volume":"112","author":"Smith","year":"2005","journal-title":"The Caerphilly Study. Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11892-006-0052-5","article-title":"Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes","volume":"6","author":"Trost","year":"2006","journal-title":"Curr Diab Rep."},{"key":"10.4158\/EP171764.APPGL_bb1035","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/01.CIR.102.14.1634","article-title":"Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population","volume":"102","author":"Stec","year":"2000","journal-title":"Circulation."},{"issue":"Suppl H","key":"10.4158\/EP171764.APPGL_bb1040","first-page":"H11","article-title":"Fibrinogen as a risk factor for coronary heart disease","volume":"102","author":"Montalescot","year":"1998","journal-title":"Eur Heart J."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb1045","first-page":"S13","article-title":"Fibrinogen and cardiovascular risk markers","volume":"10","author":"Folsom","year":"1999","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb1050","first-page":"S87","article-title":"Clinical benefit of fibrinogen evaluation","volume":"10","author":"Lowe","year":"1999","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb1055","first-page":"S29","article-title":"Should fibrinogen be measured routinely in patients with unstable coronary heart disease?","volume":"10","author":"Mehta","year":"1999","journal-title":"Blood Coagul Fibrinolysis."},{"key":"10.4158\/EP171764.APPGL_bb1060","doi-asserted-by":"crossref","first-page":"933","DOI":"10.7326\/0003-4819-130-11-199906010-00018","article-title":"Evaluating novel cardiovascular risk factors: can we better predict heart attacks?","volume":"130","author":"Ridker","year":"1999","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1065","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1070","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1075","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1161\/01.CIR.103.13.1813","article-title":"High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease","volume":"103","author":"Ridker","year":"2001","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1080","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.CIR.97.20.2007","article-title":"C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction","volume":"97","author":"Ridker","year":"1998","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1085","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","article-title":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"109","author":"Ballantyne","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1090","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1161\/01.CIR.0000143377.53389.C8","article-title":"Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany","volume":"110","author":"Koenig","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1095","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1161\/01.ATV.19.12.2909","article-title":"Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions","volume":"19","author":"H\u00e4kkinen","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb1100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/01.CIR.99.3.361","article-title":"Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery","volume":"99","author":"Laine","year":"1999","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/bj3380479","article-title":"Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor","volume":"338","author":"MacPhee","year":"1999","journal-title":"Biochem J."},{"key":"10.4158\/EP171764.APPGL_bb1110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00041433-200308000-00002","article-title":"Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease","volume":"14","author":"Caslake","year":"2003","journal-title":"Curr Opin Lipidol."},{"key":"10.4158\/EP171764.APPGL_bb1115","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM200010193431603","article-title":"Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group","volume":"343","author":"Packard","year":"2000","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1120","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1373\/clinchem.2006.066845","article-title":"High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients","volume":"52","author":"Corsetti","year":"2006","journal-title":"Clin Chem."},{"key":"10.4158\/EP171764.APPGL_bb1125","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.ATV.0000222983.73369.c8","article-title":"Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress","volume":"26","author":"Koenig","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb1130","first-page":"341","article-title":"Homocysteine and arterial occlusive disease: a concise review","volume":"44","author":"Andreotti","year":"1999","journal-title":"Cardiologia."},{"key":"10.4158\/EP171764.APPGL_bb1135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/10641969909068660","article-title":"Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix","volume":"21","author":"Tyagi","year":"1999","journal-title":"Clin Exp Hypertens."},{"key":"10.4158\/EP171764.APPGL_bb1140","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM199707243370403","article-title":"Plasma homocysteine levels and mortality in patients with coronary artery disease","volume":"337","author":"Nyg\u00e5rd","year":"1997","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-0037-1614438","article-title":"Hyperhomocysteinemia, atherosclerosis and thrombosis","volume":"81","author":"Cattaneo","year":"1999","journal-title":"Thromb Haemost."},{"key":"10.4158\/EP171764.APPGL_bb1150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0021-9150(89)90218-9","article-title":"Transient changes of serum lipoprotein(a) as an acute phase protein","volume":"78","author":"Maeda","year":"1989","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb1155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00365519209088771","article-title":"Lipoprotein(a) and acute-phase proteins in acute myocardial infarction","volume":"52","author":"Slunga","year":"1992","journal-title":"Scand J Clin Lab Invest."},{"key":"10.4158\/EP171764.APPGL_bb1160","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1161\/01.STR.26.5.795","article-title":"Plasma homocysteine in the acute and convalescent phases after stroke","volume":"26","author":"Lindgren","year":"1995","journal-title":"Stroke."},{"key":"10.4158\/EP171764.APPGL_bb1165","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0002-9149(97)89213-2","article-title":"Serial measures of plasma homocyst(e) ine after acute myocardial infarction","volume":"77","author":"Egerton","year":"1996","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1170","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1161\/01.ATV.17.10.1947","article-title":"Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial","volume":"17","author":"Evans","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb1175","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/01.CIR.98.3.204","article-title":"Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study","volume":"98","author":"Folsom","year":"1998","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1180","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.amjcard.2009.12.045","article-title":"Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA","volume":"105","author":"Park","year":"2010","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1185","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jacc.2011.05.028","article-title":"Homocysteine and reclassification of cardiovascular disease risk","volume":"58","author":"Veeranna","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00392-004-0075-3","article-title":"Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases","volume":"93","author":"Stanger","year":"2004","journal-title":"Z Kardiol."},{"key":"10.4158\/EP171764.APPGL_bb1195","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jama.291.5.565","article-title":"Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial","volume":"291","author":"Toole","year":"2004","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1200","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa055227","article-title":"Homocysteine lowering and cardiovascular events after acute myocardial infarction","volume":"354","author":"B\u00f8naa","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1205","first-page":"1567","article-title":"Homocysteine lowering with folic acid and B vitamins in vascular disease. (Erratum in: N Engl J Med. 2006;355:746)","volume":"354","author":"Lonn","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1210","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-146-11-200706050-00157","article-title":"Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial","volume":"146","author":"Ray","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1215","article-title":"U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute. Pediatric cardiovascular risk reduction initiative: background","year":"2008"},{"key":"10.4158\/EP171764.APPGL_bb1220","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","article-title":"Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey","volume":"283","author":"Fang","year":"2000","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","article-title":"Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study","volume":"131","author":"Culleton","year":"1999","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1230","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb1235","first-page":"S1","article-title":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.4158\/EP171764.APPGL_bb1240","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1245","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/art.24537","article-title":"Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses\u2019 health study","volume":"61","author":"Hak","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.4158\/EP171764.APPGL_bb1250","first-page":"292","article-title":"High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity","volume":"27","author":"Papadakis","year":"2009","journal-title":"Clin Exp Rheumatol."},{"key":"10.4158\/EP171764.APPGL_bb1255","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/CIRCULATIONAHA.107.189622","article-title":"State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV\/AIDS: executive summary. (Erratum in: Circulation. 2008;118:e109)","volume":"118","author":"Grinspoon","year":"2008","journal-title":"Circulation"},{"key":"10.4158\/EP171764.APPGL_bb1260","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1161\/01.CIR.103.22.2705","article-title":"High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound","volume":"103","author":"Tuzcu","year":"2001","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1265","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1001\/archinte.163.15.1787","article-title":"Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study","volume":"163","author":"Oren","year":"2003","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1270","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00000441-200509000-00001","article-title":"Cardiovascular risk profile of asymptomatic healthy young adults with increased femoral artery intima-media thickness: The Bogalusa Heart Study","volume":"330","author":"Paul","year":"2005","journal-title":"Am J Med Sci."},{"key":"10.4158\/EP171764.APPGL_bb1275","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","article-title":"Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials","volume":"166","author":"Thavendiranathan","year":"2006","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1280","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/CIRCULATIONAHA.105.552737","article-title":"Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium","volume":"113","author":"Goff","year":"2006","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1285","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/00007611-198911000-00010","article-title":"Population screening for plasma cholesterol: community-based results from Atlanta","volume":"82","author":"Harris","year":"1989","journal-title":"South Med J."},{"key":"10.4158\/EP171764.APPGL_bb1290","first-page":"853","article-title":"Population screening for plasma cholesterol: community-based results from Miami","volume":"76","author":"Harris","year":"1989","journal-title":"J Fla Med Assoc."},{"key":"10.4158\/EP171764.APPGL_bb1295","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0002-8703(89)90741-2","article-title":"Population screening for plasma cholesterol: community-based results from Connecticut","volume":"117","author":"Wynder","year":"1989","journal-title":"Am Heart J."},{"key":"10.4158\/EP171764.APPGL_bb1300","first-page":"1","article-title":"Deaths: final data for 2003","volume":"54","author":"Hoyert","year":"2006","journal-title":"Natl Vital Stat Rep."},{"key":"10.4158\/EP171764.APPGL_bb1305","first-page":"e85","article-title":"Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. (Erratum in: Circulation. 2006;113:e696 and Circulation. 2006;114:e630)","volume":"113","author":"Thom","year":"2006","journal-title":"Circulation"},{"key":"10.4158\/EP171764.APPGL_bb1310","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","year":"1998","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1315","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/01.CIR.99.2.216","article-title":"Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study","volume":"99","author":"Plehn","year":"1999","journal-title":"The Care Investigators. Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1320","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/jama.293.4.477","article-title":"Angina with \u201cnormal\u201d coronary arteries: a changing philosophy","volume":"293","author":"Bugiardini","year":"2005","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1325","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/eurheartj\/ehi758","article-title":"Women, \u2018non-specific\u2019 chest pain, and normal or near-normal coronary angiograms are not synonymous with favourable outcome","volume":"27","author":"Bugiardini","year":"2006","journal-title":"Eur Heart J."},{"key":"10.4158\/EP171764.APPGL_bb1330","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/archinte.164.15.1610","article-title":"Utility of stress testing and coronary calcification measurement for detection of coronary artery disease in women","volume":"164","author":"Nasir","year":"2004","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1335","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1340","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0167-5273(90)90310-2","article-title":"Atherogenesis and the coronary arteries of childhood","volume":"28","author":"Davies","year":"1990","journal-title":"Int J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1345","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0735-1097(93)90050-B","article-title":"Manifestations of coronary atherosclerosis in young trauma victims--an autopsy study","volume":"22","author":"Joseph","year":"1993","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1350","doi-asserted-by":"crossref","first-page":"30T","DOI":"10.1016\/S0002-9149(98)00720-6","article-title":"Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group","volume":"82","author":"McGill","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1355","article-title":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents Full Report","author":"Daniels","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb1360","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJM198601163140302","article-title":"Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study","volume":"314","author":"Newman","year":"1986","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1365","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1056\/NEJM199302043280504","article-title":"Serum cholesterol in young men and subsequent cardiovascular disease","volume":"328","author":"Klag","year":"1993","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb1370","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00000441-199512000-00007","article-title":"Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa Heart Study","volume":"310","author":"Tracy","year":"1995","journal-title":"Am J Med Sci"},{"key":"10.4158\/EP171764.APPGL_bb1375","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1001\/jama.290.17.2271","article-title":"Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study","volume":"290","author":"Li","year":"2003","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1380","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0022-3476(88)80709-1","article-title":"The pediatrician\u2019s role in atherosclerosis prevention","volume":"112","author":"Jacobson","year":"1988","journal-title":"J Pediatr."},{"key":"10.4158\/EP171764.APPGL_bb1385","first-page":"525","article-title":"American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents","volume":"89","year":"1992","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb1390","first-page":"105","article-title":"Preventive nutrition in childhood: a rationale","volume":"24","author":"Deckelbaum","year":"1996","journal-title":"Public Health Rev."},{"key":"10.4158\/EP171764.APPGL_bb1395","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2165\/00002018-199716050-00004","article-title":"A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits","volume":"16","author":"Tonstad","year":"1997","journal-title":"Drug Saf."},{"key":"10.4158\/EP171764.APPGL_bb1400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3476(98)70167-2","article-title":"Heart healthy diets for all children: no longer controversial","volume":"133","author":"Jacobson","year":"1998","journal-title":"J Pediatr."},{"key":"10.4158\/EP171764.APPGL_bb1405","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1006\/pmed.1998.0356","article-title":"Normal growth in high-risk hyperlipidemic children and adolescents with dietary intervention","volume":"27","author":"Jacobson","year":"1998","journal-title":"Prev Med."},{"key":"10.4158\/EP171764.APPGL_bb1410","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jama.281.8.727","article-title":"Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study","volume":"281","author":"Strong","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1415","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1542\/peds.2008-1349","article-title":"Committee on Nutrition. Lipid screening and cardiovascular health in childhood","volume":"122","author":"Daniels","year":"2008","journal-title":"Pediatrics."},{"issue":"Suppl","key":"10.4158\/EP171764.APPGL_bb1420","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1080\/07315724.1992.10737973","article-title":"Conclusions, guidelines and recommendations from the IUNS\/WHO Workshop: nutrition in the pediatric age group and later cardiovascular disease","volume":"11","author":"Akerblom","year":"1992","journal-title":"J Am Coll Nutr."},{"key":"10.4158\/EP171764.APPGL_bb1425","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1542\/peds.101.1.141","volume":"101","year":"1998","journal-title":"Pediatrics"},{"key":"10.4158\/EP171764.APPGL_bb1430","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1161\/CIRCULATIONAHA.107.181946","volume":"115","author":"McCrindle","year":"2007","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1435","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1542\/peds.98.3.383","article-title":"Failure of current guidelines for cholesterol screening in urban African-American adolescents","volume":"98","author":"Rifai","year":"1996","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb1440","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1542\/peds.78.2.349","article-title":"Biochemical, clinical, epidemiologic, genetic, and pathologic data in the pediatric age group relevant to the cholesterol hypothesis","volume":"78","author":"Kwiterovich","year":"1986","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb1445","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/oxfordjournals.aje.a115968","article-title":"Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study","volume":"133","author":"Webber","year":"1991","journal-title":"Am J Epidemiol."},{"key":"10.4158\/EP171764.APPGL_bb1450","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/ajcn\/67.6.1106","article-title":"Dietary fat controversy: is it also applicable to children?","volume":"67","author":"Kasim-Karakas","year":"1998","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb1455","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1210\/jcem.81.3.8772576","article-title":"Insulin sensitivity, lipids, and body composition in childhood: is \u201csyndrome X\u201d present?","volume":"81","author":"Arslanian","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP171764.APPGL_bb1460","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/01.CIR.0000061521.15730.6E","article-title":"American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood","volume":"107","author":"Kavey","year":"2003","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1465","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1470","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/clinchem\/48.2.236","article-title":"Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation","volume":"48","author":"Nauck","year":"2002","journal-title":"Clin Chem."},{"key":"10.4158\/EP171764.APPGL_bb1475","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1592\/phco.24.2.167.33142","article-title":"A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level","volume":"24","author":"Lindsey","year":"2004","journal-title":"Pharmacotherapy."},{"key":"10.4158\/EP171764.APPGL_bb1480","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.CIR.0000081777.17879.85","article-title":"Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study","volume":"108","author":"Hopkins","year":"2003","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1485","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/clinchem\/46.8.1121","article-title":"Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients","volume":"46","author":"Esteban-Sal\u00e1n","year":"2000","journal-title":"Clin Chem."},{"key":"10.4158\/EP171764.APPGL_bb1490","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00001573-200311000-00012","article-title":"Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials","volume":"18","author":"Xydakis","year":"2003","journal-title":"Curr Opin Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1495","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/diacare.26.1.240","article-title":"Non-HDL cholesterol: into the spotlight","volume":"26","author":"Hsia","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb1500","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2337\/diacare.26.1.16","article-title":"Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study","volume":"26","author":"Lu","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb1505","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1210\/jc.2007-0453","article-title":"Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes","volume":"92","author":"Jialal","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP171764.APPGL_bb1510","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/01.CIR.0000038496.57570.06","article-title":"Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI)","volume":"106","author":"Bittner","year":"2002","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1515","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.105.583336","article-title":"Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is","volume":"112","author":"Sniderman","year":"2005","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1520","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jacc.2009.11.073","article-title":"Carotid intima-media thickness, plaques, and cardiovascular disease risk: implications for preventive cardiology guidelines","volume":"55","author":"Stein","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1525","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1161\/01.ATV.12.11.1336","article-title":"Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state","volume":"12","author":"Patsch","year":"1992","journal-title":"Arterioscler Thromb."},{"issue":"Suppl 4","key":"10.4158\/EP171764.APPGL_bb1530","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1002\/(SICI)1096-9136(1998120)15:4+<S63::AID-DIA737>3.0.CO;2-7","article-title":"The postprandial state and risk of cardiovascular disease","volume":"15","author":"Lef\u00e8bvre","year":"1998","journal-title":"Diabet Med."},{"key":"10.4158\/EP171764.APPGL_bb1535","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/10408369891234255","article-title":"The atherogenic significance of an elevated plasma triglyceride level","volume":"35","author":"Ooi","year":"1998","journal-title":"Crit Rev Clin Lab Sci."},{"key":"10.4158\/EP171764.APPGL_bb1540","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/01.CIR.100.7.723","article-title":"Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men","volume":"100","author":"Boquist","year":"1999","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1545","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0026-0495(99)90076-8","article-title":"Differences in post-prandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease","volume":"48","author":"Karpe","year":"1999","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb1550","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1464-5491.2001.00386.x","article-title":"Maximal post-prandial triglyceride increase reflects post-prandial hypertriglyceridaemia and is associated with the insulin resistance syndrome","volume":"18","author":"Karamanos","year":"2001","journal-title":"Diabet Med."},{"key":"10.4158\/EP171764.APPGL_bb1555","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cll.2006.07.003","article-title":"Postprandial lipemia and remnant lipoproteins","volume":"26","author":"Cohn","year":"2006","journal-title":"Clin Lab Med."},{"key":"10.4158\/EP171764.APPGL_bb1560","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb1565","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1161\/01.CIR.0000146339.57154.9B","article-title":"Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines","volume":"110","author":"Shai","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1570","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1161\/01.CIR.0000145660.60487.94","article-title":"Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study","volume":"110","author":"Sattar","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1575","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11883-009-0054-2","article-title":"ApoB versus non-HDL-C: what to do when they disagree","volume":"11","author":"Sniderman","year":"2009","journal-title":"Curr Atheroscler Rep."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb1580","first-page":"1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus (Erratum in Endocr Pract. ;14:802-803)","volume":"13","author":"Rodbard","year":"2008","journal-title":"Endocr Pract"},{"key":"10.4158\/EP171764.APPGL_bb1585","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjcard.2012.04.062","article-title":"Secondary causes of dyslipidemia","volume":"110","author":"Vodnala","year":"2012","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1590","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1595","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1001\/archinte.165.18.2063","article-title":"High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey","volume":"165","author":"Miller","year":"2005","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1600","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"issue":"9","key":"10.4158\/EP171764.APPGL_bb1605","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.STR.24.9.1297","article-title":"Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound","volume":"24","author":"Howard","year":"1993","journal-title":"ARIC Investigators. Stroke."},{"key":"10.4158\/EP171764.APPGL_bb1610","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis","volume":"115","author":"Lorenz","year":"2007","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1615","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. (Erratum in: JAMA. 1988;259:2698)","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"10.4158\/EP171764.APPGL_bb1620","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1625","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-119-10-199311150-00002","article-title":"Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)","volume":"119","author":"Blankenhorn","year":"1993","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1630","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1635","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1640","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.4158\/EP171764.APPGL_bb1645","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1650","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.105.568147","article-title":"Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial","volume":"113","author":"Schmermund","year":"2006","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1655","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP171764.APPGL_bb1660","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1665","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia. (Erratum in: N Engl J Med. 2008;358:1977)","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1670","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on Progression of Coronary Disease in Statin- Treated Patients: The GLAGOV Randomized Clinical Trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1675","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1161\/01.CIR.94.5.1175","article-title":"Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group","volume":"94","author":"Wexler","year":"1996","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1680","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/aje\/kwf113","article-title":"Multi-Ethnic Study of Atherosclerosis: objectives and design","volume":"156","author":"Bild","year":"2002","journal-title":"Am J Epidemiol."},{"key":"10.4158\/EP171764.APPGL_bb1685","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003186","article-title":"Coronary artery calcium improves risk assessment in adults with a family history of premature coronary heart disease: Results From Multiethnic Study of Atherosclerosis","volume":"8","author":"Patel","year":"2015","journal-title":"Circ Cardiovasc Imaging."},{"key":"10.4158\/EP171764.APPGL_bb1690","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacc.2015.10.058","article-title":"Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment","volume":"67","author":"Yeboah","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1695","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/eurheartj\/eht508","article-title":"Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis","volume":"35","author":"Silverman","year":"2014","journal-title":"Eur Heart J."},{"key":"10.4158\/EP171764.APPGL_bb1700","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.atherosclerosis.2016.01.017","article-title":"Coronary artery calcium predicts cardiovascular events in participants with a low lifetime risk of cardiovascular disease: The Multi- Ethnic Study of Atherosclerosis (MESA)","volume":"246","author":"Joshi","year":"2016","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb1705","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.115.018524","article-title":"Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: The Multi- Ethnic Study of Atherosclerosis (MESA)","volume":"133","author":"Blaha","year":"2016","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1710","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MOL.0000000000000325","article-title":"Diagnostic scoring for familial hypercholesterolaemia in practice","volume":"27","author":"Haralambos","year":"2016","journal-title":"Curr Opin Lipidol."},{"issue":"Suppl A","key":"10.4158\/EP171764.APPGL_bb1715","first-page":"5A","article-title":"Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study","volume":"4","author":"Castelli","year":"1988","journal-title":"Can J Cardiol"},{"key":"10.4158\/EP171764.APPGL_bb1720","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1001\/archinte.1993.00410190045006","article-title":"Plasma lipoprotein levels as predictors of cardiovascular death in women","volume":"153","author":"Bass","year":"1993","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1725","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1730","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1735","doi-asserted-by":"crossref","first-page":"8A","DOI":"10.1016\/S0002-9149(05)80010-4","article-title":"Clustering of cardiovascular risk factors: targeting high-risk individuals","volume":"76","author":"Genest","year":"1995","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1740","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1745","first-page":"1849","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. (Erratum in: Lancet. 2006;368:1415 and Lancet. 2006;368:1420)","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.4158\/EP171764.APPGL_bb1750","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archinte.166.7.743","article-title":"Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study","volume":"166","author":"Tenkanen","year":"2006","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1755","first-page":"333","article-title":"Is there an optimal diet for the hypertriglyceridemic patient?","volume":"7","author":"Kris-Etherton","year":"2000","journal-title":"J Cardiovasc Risk."},{"key":"10.4158\/EP171764.APPGL_bb1760","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb1765","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2004.03.042","article-title":"A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women","volume":"94","author":"Goldberg","year":"2004","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1770","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/diacare.28.4.888","article-title":"Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program","volume":"28","author":"Ratner","year":"2005","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb1775","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","article-title":"Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial","volume":"30","author":"Ahead Look Research Group","year":"2007","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb1780","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/ajcn\/51.3.399","article-title":"Fish oils in hypertriglyceridemia: a dose-response study","volume":"51","author":"Harris","year":"1990","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb1785","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","article-title":"Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g\/d to simvastatin 40 mg\/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther."},{"key":"10.4158\/EP171764.APPGL_bb1790","author":"Balk"},{"key":"10.4158\/EP171764.APPGL_bb1795","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0026-0495(76)90089-5","article-title":"Myocardial infarction in the familial forms of hypertriglyceridemia","volume":"25","author":"Brunzell","year":"1976","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb1800","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1161\/01.CIR.101.24.2777","article-title":"Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study","volume":"101","author":"Austin","year":"2000","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1805","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJM198006193022503","article-title":"Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease","volume":"302","author":"Hulley","year":"1980","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1810","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jama.1991.03460070086049","article-title":"The familial hyper-chylomicronemia syndrome. New insights into underlying genetic defects","volume":"265","author":"Santamarina-Fojo","year":"1991","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1815","doi-asserted-by":"crossref","first-page":"30F","DOI":"10.1016\/S0002-9149(99)00270-2","article-title":"Role of fibrates in the management of hypertriglyceridemia","volume":"83","author":"Rader","year":"1999","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb1825","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ."},{"key":"10.4158\/EP171764.APPGL_bb1830","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00007256-200636050-00006","article-title":"Physical activity and high-sensitivity C-reactive protein","volume":"36","author":"Plaisance","year":"2006","journal-title":"Sports Med."},{"key":"10.4158\/EP171764.APPGL_bb1835","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJM199302253280804","article-title":"The association of changes in physical-activity level and other lifestyle characteristics with mortality among men","volume":"328","author":"Paffenbarger","year":"1993","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1840","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jama.1995.03520290054029","article-title":"Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine","volume":"273","author":"Pate","year":"1995","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1845","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"10.4158\/EP171764.APPGL_bb1850","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJM199908263410904","article-title":"A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women","volume":"341","author":"Manson","year":"1999","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1855","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1161\/01.CIR.102.18.2284","article-title":"AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association","volume":"102","author":"Krauss","year":"2000","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1860","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1097\/00005768-200106001-00003","article-title":"Dose-response issues concerning physical activity and health: an evidence-based symposium","volume":"33","author":"Kesaniemi","year":"2001","journal-title":"Med Sci Sports Exerc."},{"key":"10.4158\/EP171764.APPGL_bb1865","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa021067","article-title":"Walking compared with vigorous exercise for the prevention of cardiovascular events in women","volume":"347","author":"Manson","year":"2002","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1870","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1001\/jama.289.18.2379","article-title":"Relationship of changes in physical activity and mortality among older women","volume":"289","author":"Gregg","year":"2003","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1875","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.107.185649","article-title":"Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association","volume":"116","author":"Haskell","year":"2007","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1885","first-page":"893","article-title":"Prescribing exercise in multiple short bouts versus one continuous bout: effects on adherence, cardiorespiratory fitness, and weight loss in overweight women","volume":"19","author":"Jakicic","year":"1995","journal-title":"Int J Obes Relat Metab Disord."},{"key":"10.4158\/EP171764.APPGL_bb1890","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.ijo.0801198","article-title":"The effects of 18 months of intermittent vs. continuous exercise on aerobic capacity, body weight and composition, and metabolic fitness in previously sedentary, moderately obese females","volume":"24","author":"Donnelly","year":"2000","journal-title":"Int J Obes Relat Metab Disord."},{"key":"10.4158\/EP171764.APPGL_bb1895","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/00005768-200209000-00011","article-title":"Accumulating brisk walking for fitness, cardiovascular risk, and psychological health","volume":"34","author":"Murphy","year":"2002","journal-title":"Med Sci Sports Exerc."},{"key":"10.4158\/EP171764.APPGL_bb1900","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.279.9.669","article-title":"Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study","volume":"279","author":"Mayer-Davis","year":"1998","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb1905","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2337\/dc07-0841","article-title":"The effect of resistance training on functional capacity and quality of life in individuals with high and low numbers of metabolic risk factors","volume":"30","author":"Levinger","year":"2007","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb1910","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1249\/01.mss.0000247003.32589.a6","article-title":"Muscular strength, aerobic fitness, and metabolic syndrome risk in Flemish Adults","volume":"39","author":"Wijndaele","year":"2007","journal-title":"Med Sci Sports Exerc."},{"key":"10.4158\/EP171764.APPGL_bb1915","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ypmed.2008.10.010","article-title":"Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials","volume":"48","author":"Kelley","year":"2009","journal-title":"Prev Med."},{"key":"10.4158\/EP171764.APPGL_bb1920","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/diacare.26.4.1186","article-title":"Increasing physical activity in people with type 2 diabetes","volume":"26","author":"Kirk","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb1925","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/HJR.0b013e3280116485","article-title":"Effect of an exercise consultation on maintenance of physical activity after completion of phase III exercise-based cardiac rehabilitation","volume":"14","author":"Hughes","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"10.4158\/EP171764.APPGL_bb1930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11100","article-title":"Exercise Evaluation Randomised Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only","volume":"11","author":"Isaacs","year":"2007","journal-title":"Health Technol Assess."},{"key":"10.4158\/EP171764.APPGL_bb1935","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1139\/H07-023","article-title":"Strategies to enhance compliance to physical activity for patients with insulin resistance","volume":"32","author":"Kirk","year":"2007","journal-title":"Appl Physiol Nutr Metab."},{"key":"10.4158\/EP171764.APPGL_bb1940","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.ATV.12.8.911","article-title":"Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials","volume":"12","author":"Mensink","year":"1992","journal-title":"Arterioscler Thromb."},{"key":"10.4158\/EP171764.APPGL_bb1945","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2337\/diab.41.10.1278","article-title":"Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM","volume":"41","author":"Garg","year":"1992","journal-title":"Diabetes."},{"key":"10.4158\/EP171764.APPGL_bb1950","doi-asserted-by":"crossref","first-page":"577S","DOI":"10.1093\/ajcn\/67.3.577S","article-title":"High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis","volume":"67","author":"Garg","year":"1998","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb1955","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ajcn\/70.6.1009","article-title":"High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations","volume":"70","author":"Kris-Etherton","year":"1999","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb1960","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMra054035","article-title":"Trans fatty acids and cardiovascular disease","volume":"354","author":"Mozaffarian","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb1965","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/bmj.304.6833.1015","article-title":"Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up","volume":"304","author":"Singh","year":"1992","journal-title":"BMJ."},{"key":"10.4158\/EP171764.APPGL_bb1970","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1161\/01.CIR.94.7.1795","article-title":"Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association","volume":"94","author":"Krauss","year":"1996","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb1975","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/01.ATV.19.2.187","article-title":"Systematic review on the risk and benefit of different cholesterol-lowering interventions","volume":"19","author":"Bucher","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb1980","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/01.CIR.99.6.779","article-title":"Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study","volume":"99","author":"de Lorgeril","year":"1999","journal-title":"Circulation."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb1985","first-page":"S43","volume":"23","year":"2000","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171764.APPGL_bb1990","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/ajcn\/72.4.912","article-title":"Prospective study of major dietary patterns and risk of coronary heart disease in men","volume":"72","author":"Hu","year":"2000","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb1995","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ajcn\/76.1.93","article-title":"Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study","volume":"76","author":"Bazzano","year":"2002","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2000","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2005","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJM199506013322207","article-title":"Management of primary hyperlipidemia. (Erratum in: N Engl J Med. 1995;333:467)","volume":"332","author":"Havel","year":"1995","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2010","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1161\/01.CIR.95.12.2701","article-title":"Fiber, lipids, and coronary heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association","volume":"95","author":"Van Horn","year":"1997","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2015","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/ajcn\/34.5.824","article-title":"Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men","volume":"34","author":"Kirby","year":"1981","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2020","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/40.6.1146","article-title":"Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men","volume":"40","author":"Anderson","year":"1984","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2025","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/ajcn\/51.6.1013","article-title":"Serum lipid response of hypercholesterolemic men to single and divided doses of canned beans","volume":"51","author":"Anderson","year":"1990","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ajcn\/52.3.495","article-title":"Oat-bran cereal lowers serum total and LDL cholesterol in hypercholesterolemic men","volume":"52","author":"Anderson","year":"1990","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2035","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/ajcn\/54.4.678","article-title":"Lipid responses of hypercholesterolemic men to oat-bran and wheat-bran intake","volume":"54","author":"Anderson","year":"1991","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2050","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0026-0495(99)90053-7","article-title":"Cholesterol reduction by different plant stanol mixtures and with variable fat intake","volume":"48","author":"Gylling","year":"1999","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb2055","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0022-2275(20)32138-6","article-title":"Serum sterols during stanol ester feeding in a mildly hypercholesterolemic population","volume":"40","author":"Gylling","year":"1999","journal-title":"J Lipid Res."},{"key":"10.4158\/EP171764.APPGL_bb2060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ajcn\/69.3.403","article-title":"Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects","volume":"69","author":"Hallikainen","year":"1999","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00041433-199902000-00003","article-title":"Regulation of cholesterol metabolism by dietary plant sterols","volume":"10","author":"Miettinen","year":"1999","journal-title":"Curr Opin Lipidol."},{"key":"10.4158\/EP171764.APPGL_bb2070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM198603203141204","article-title":"Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol","volume":"314","author":"Grundy","year":"1986","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(87)91965-9","article-title":"Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women","volume":"1","author":"Mensink","year":"1987","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb2080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2337\/diacare.18.1.10","article-title":"Why do low-fat high-carbohydrate diets accentuate postprandial lipemia in patients with NIDDM?","volume":"18","author":"Chen","year":"1995","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb2085","first-page":"1509","article-title":"Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men","volume":"278","author":"Knopp","year":"1997","journal-title":"The Dietary Alternatives Study. JAMA."},{"key":"10.4158\/EP171764.APPGL_bb2090","first-page":"563","article-title":"Should a low-fat, high-carbohydrate diet be recommended for everyone? Beyond low-fat diets","volume":"337","author":"Katan","year":"1997","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2100","doi-asserted-by":"crossref","first-page":"1645S","DOI":"10.1093\/ajcn\/65.5.1645S","article-title":"n-3 fatty acids and serum lipoproteins: human studies","volume":"65","author":"Harris","year":"1997","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2105","doi-asserted-by":"crossref","first-page":"II40","DOI":"10.1002\/clc.4960221408","article-title":"Nonpharmacologic treatment of hypertriglyceridemia: focus on fish oils","volume":"22","author":"Harris","year":"1999","journal-title":"Clin Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2110","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1001\/jama.296.15.1885","article-title":"Fish intake, contaminants, and human health: evaluating the risks and the benefits. (Erratum in: JAMA. 2007;297:590)","volume":"296","author":"Mozaffarian","year":"2006","journal-title":"JAMA"},{"key":"10.4158\/EP171764.APPGL_bb2115","doi-asserted-by":"crossref","first-page":"1991S","DOI":"10.1093\/ajcn\/87.6.1991S","article-title":"Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death","volume":"87","author":"Mozaffarian","year":"2008","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2120","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/CIRCULATIONAHA.115.019949","article-title":"Effect of Omega-3 acid ethyl esters on left ventricular Remodeling after acute myocardial infarction: The OMEGA-REMODEL Randomized Clinical Trial","volume":"134","author":"Heydari","year":"2016","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2130","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.amjcard.2009.05.055","article-title":"Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease","volume":"104","author":"Watson","year":"2009","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/01.ATV.17.2.375","article-title":"Lipoprotein lipid response to the National Cholesterol Education Program step II diet by hypercholesterolemic and combined hyperlipidemic women and men","volume":"17","author":"Walden","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb2140","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/jama.280.23.2001","article-title":"Intensive lifestyle changes for reversal of coronary heart disease. (Erratum in: JAMA. 1999;281:1380)","volume":"280","author":"Ornish","year":"1998","journal-title":"JAMA"},{"key":"10.4158\/EP171764.APPGL_bb2145","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.297.9.969","article-title":"Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight pre-menopausal women: the A TO Z Weight Loss Study: a randomized trial. (Erratum in: JAMA. 2007;298:178)","volume":"297","author":"Gardner","year":"2007","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.4158\/EP171764.APPGL_bb2150","doi-asserted-by":"crossref","first-page":"533S","DOI":"10.1093\/ajcn\/78.3.533S","article-title":"Mortality in British vegetarians: review and preliminary results from EPIC-Oxford","volume":"78","author":"Key","year":"2003","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2155","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM197505292922203","article-title":"Plasma lipids and lipoproteins in vegetarians and controls","volume":"292","author":"Sacks","year":"1975","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2160","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jama.1981.03320060042020","article-title":"Effect of ingestion of meat on plasma cholesterol of vegetarians","volume":"246","author":"Sacks","year":"1981","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb2165","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1753-4887.1993.tb03115.x","article-title":"New recommendations for the diagnosis and treatment of plasma lipid abnormalities","volume":"51","author":"Schaefer","year":"1993","journal-title":"Nutr Rev."},{"key":"10.4158\/EP171764.APPGL_bb2170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1096\/fasebj.8.1.8299884","article-title":"Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men","volume":"8","author":"Dreon","year":"1994","journal-title":"FASEB J."},{"key":"10.4158\/EP171764.APPGL_bb2175","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/01.ATV.17.4.707","article-title":"LDL subclass patterns and lipoprotein response to a low-fat, high-carbohydrate diet in women","volume":"17","author":"Dreon","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb2180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/000331979804900502","article-title":"Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease","volume":"49","author":"Borgia","year":"1998","journal-title":"Angiology."},{"key":"10.4158\/EP171764.APPGL_bb2185","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.metabol.2007.05.004","article-title":"Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents","volume":"56","author":"Caranti","year":"2007","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb2190","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1740-8709.2009.00207.x","article-title":"Effects of a lifestyle modification trial among phenotypically obese metabolically normal and phenotypically obese metabolically abnormal adolescents in comparison with phenotypically normal metabolically obese adolescents","volume":"6","author":"Kelishadi","year":"2010","journal-title":"Matern Child Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2195","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1542\/peds.2010-0697","article-title":"Long-term results of an obesity program in an ethnically diverse pediatric population","volume":"127","author":"Savoye","year":"2011","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb2200","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1001\/jama.1990.03450230075032","article-title":"The case against childhood cholesterol screening","volume":"264","author":"Newman","year":"1990","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb2205","first-page":"22A","article-title":"The effect of dietary therapy on growth in hyperlipidemic children and adolescents: a prospective clinical trial [Abstract]","volume":"25","author":"Budow","year":"1989","journal-title":"Pediatr Res"},{"key":"10.4158\/EP171764.APPGL_bb2210","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1542\/peds.84.3.475","article-title":"Growth of vegetarian children: The Farm Study","volume":"84","author":"O\u2019Connell","year":"1989","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb2215","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1542\/peds.92.4.579","article-title":"Is there a relationship between dietary fat and stature or growth in children three to five years of age?","volume":"92","author":"Shea","year":"1993","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb2220","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1651-2227.1995.tb13597.x","article-title":"Effects of differences in dietary fat on growth, energy and nutrient intake from infancy to eight years of age","volume":"84","author":"Boulton","year":"1995","journal-title":"Acta Paediatr"},{"key":"10.4158\/EP171764.APPGL_bb2225","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archpedi.1995.02170150113022","article-title":"Nutrient quality of fat-and cholesterol-modified diets of children with hyperlipidemia","volume":"149","author":"Copperman","year":"1995","journal-title":"Arch Pediatr Adolesc Med."},{"key":"10.4158\/EP171764.APPGL_bb2230","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(95)90580-4","article-title":"Prospective randomised trial in 1062 infants of diet low in saturated fat and cholesterol","volume":"345","author":"Lapinleimu","year":"1995","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb2235","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1161\/01.CIR.94.6.1386","article-title":"Prospective randomized trial of low-saturated-fat, low-cholesterol diet during the first 3 years of life. The STRIP baby project","volume":"94","author":"Niinikoski","year":"1996","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2240","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1542\/peds.100.5.810","article-title":"Regulation of growth of 7-to 36-month-old children by energy and fat intake in the prospective, randomized STRIP baby trial","volume":"100","author":"Niinikoski","year":"1997","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb2245","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1542\/peds.100.1.51","article-title":"Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC)","volume":"100","author":"Obarzanek","year":"1997","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb2250","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-3476(98)70173-8","article-title":"Growth of hypercholesterolemic children completing physician-initiated low-fat dietary intervention","volume":"133","author":"Tershakovec","year":"1998","journal-title":"J Pediatr."},{"key":"10.4158\/EP171764.APPGL_bb2255","first-page":"378","article-title":"Effects of nutritional counseling on lipoprotein levels in a pediatric lipid clinic","volume":"147","author":"Mietus-Snyder","year":"1993","journal-title":"Am J Dis Child."},{"issue":"Suppl","key":"10.4158\/EP171764.APPGL_bb2260","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/0021-9150(94)90153-8","article-title":"Dyslipoproteinemia and other risk factors for atherosclerosis in children and adolescents","volume":"108","author":"Kwiterovich","year":"1994","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb2265","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.1995.03520420045036","article-title":"Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC)","volume":"273","year":"1995","journal-title":"JAMA"},{"key":"10.4158\/EP171764.APPGL_bb2270","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s004310050966","article-title":"Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy","volume":"157","author":"Hennermann","year":"1998","journal-title":"Eur J Pediatr."},{"key":"10.4158\/EP171764.APPGL_bb2275","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ajcn\/67.6.1147","article-title":"Greater dietary intake of simple carbohydrate is associated with lower concentrations of high-density-lipoprotein cholesterol in hypercholesterolemic children","volume":"67","author":"Starc","year":"1998","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/EP171764.APPGL_bb2280","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1542\/peds.88.2.265","article-title":"Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy","volume":"88","author":"Goren","year":"1991","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb2285","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1161\/CIRCULATIONAHA.105.169251","article-title":"Dietary recommendations for children and adolescents: a guide for practitioner: consensus statement from the American Heart Association. (Errata in: Circulation. 2005;112:2375 and Circulation. 2006;113:e857)","volume":"112","author":"Gidding","year":"2005","journal-title":"Circulation"},{"key":"10.4158\/EP171764.APPGL_bb2290","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2006.09.011","article-title":"Effect of a short-term diet and exercise intervention in youth on atherosclerotic risk factors","volume":"191","author":"Roberts","year":"2007","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb2295","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1651-2227.2002.tb00121.x","article-title":"Effects of gender, apolipoprotein E phenotype and cholesterol-lowering by plant stanol esters in children: the STRIP study. Special Turku Coronary Risk Factor Intervention Project","volume":"91","author":"Tammi","year":"2002","journal-title":"Acta Paediatr."},{"key":"10.4158\/EP171764.APPGL_bb2300","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.103.8.1177","article-title":"AHA Science Advisory. Stanol\/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association","volume":"103","author":"Lichtenstein","year":"2001","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2305","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00041433-199608000-00002","article-title":"Serum lipoproteins in children and young adults: determinants and treatment strategies","volume":"7","author":"Porkka","year":"1996","journal-title":"Curr Opin Lipidol."},{"key":"10.4158\/EP171764.APPGL_bb2310","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/oxfordjournals.aje.a117543","article-title":"Clustering of risk habits in young adults. The Cardiovascular Risk in Young Finns Study","volume":"142","author":"Raitakari","year":"1995","journal-title":"Am J Epidemiol."},{"key":"10.4158\/EP171764.APPGL_bb2315","series-title":"Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline","author":"Fiore","year":"2008"},{"key":"10.4158\/EP171764.APPGL_bb2320","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","volume":"40","year":"1978","journal-title":"Br Heart J"},{"key":"10.4158\/EP171764.APPGL_bb2325","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.4158\/EP171764.APPGL_bb2330","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2335","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2340","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb2345","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ."},{"key":"10.4158\/EP171764.APPGL_bb2350","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"10.4158\/EP171764.APPGL_bb2355","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb2360","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb2365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00003495-198600311-00010","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial","volume":"31","author":"Rifkind","year":"1986","journal-title":"Drugs."},{"issue":"Suppl 2","key":"10.4158\/EP171764.APPGL_bb2370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","volume":"64","author":"Sever","year":"2004","journal-title":"Drugs."},{"key":"10.4158\/EP171764.APPGL_bb2375","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.amjcard.2007.09.072","article-title":"Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein","volume":"100","author":"Ridker","year":"2007","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2380","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1749-6632.1994.tb17337.x","article-title":"Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study","volume":"748","author":"Brown","year":"1995","journal-title":"Ann N Y Acad Sci."},{"key":"10.4158\/EP171764.APPGL_bb2385","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(96)91343-4","article-title":"Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients","volume":"347","author":"Ericsson","year":"1996","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb2390","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0002-9149(97)00627-9","article-title":"Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT)","volume":"80","author":"McCormick","year":"1997","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2395","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Benzafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2400","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2018usual\u2019 care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP171764.APPGL_bb2405","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb2410","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ahj.2010.12.007","volume":"161","year":"2011","journal-title":"Am Heart J"},{"key":"10.4158\/EP171764.APPGL_bb2415","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171764.APPGL_bb2420","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-016-0332-6","article-title":"Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial","volume":"15","author":"Arbel","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"10.4158\/EP171764.APPGL_bb2435","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2440","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2337\/diacare.27.4.889","article-title":"C-reactive protein and incident cardiovascular events among men with diabetes","volume":"27","author":"Schulze","year":"2004","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb2445","series-title":"Arteriographic benefit of multifactorial risk reduction in patients with LDL-C <125 mg\/dL is seen in LDL pattern B but not pattern A","author":"Superko","year":"1997"},{"key":"10.4158\/EP171764.APPGL_bb2450","doi-asserted-by":"crossref","first-page":"63S","DOI":"10.1016\/S0002-9343(98)00214-9","article-title":"Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials","volume":"105","author":"White","year":"1998","journal-title":"Am J Med."},{"key":"10.4158\/EP171764.APPGL_bb2455","first-page":"3241","article-title":"Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial","volume":"99","author":"Campeau","year":"1999","journal-title":"Post CABG Trial Investigators. Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2460","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0002-9149(00)01172-3","article-title":"Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting","volume":"86","author":"Dotani","year":"2000","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2465","first-page":"157","article-title":"Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial","volume":"102","author":"Knatterud","year":"2000","journal-title":"Post CABG Investigators. Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2470","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-9149(01)01696-4","article-title":"Statin therapy and the acute inflammatory response after coronary artery bypass grafting","volume":"88","author":"Brull","year":"2001","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2475","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1161\/01.CIR.0000138316.24048.08","article-title":"Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery","volume":"110","author":"Pan","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2480","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/01.CCM.0000201407.89977.EA","article-title":"Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery","volume":"34","author":"Chello","year":"2006","journal-title":"Crit Care Med."},{"key":"10.4158\/EP171764.APPGL_bb2485","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.amjcard.2005.07.124","article-title":"Statins and post-operative risk of atrial fibrillation following coronary artery bypass grafting","volume":"97","author":"Mar\u00edn","year":"2006","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2490","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"key":"10.4158\/EP171764.APPGL_bb2495","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1210\/jcem.87.4.8412","article-title":"Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond","volume":"87","author":"McFarlane","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP171764.APPGL_bb2500","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.CIR.0000091404.09558.AF","article-title":"High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study","volume":"108","author":"Kinlay","year":"2003","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2505","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1210\/jc.2003-031116","article-title":"The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes","volume":"89","author":"Economides","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP171764.APPGL_bb2510","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"10.4158\/EP171764.APPGL_bb2515","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ahj.2004.07.041","article-title":"Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study","volume":"149","author":"Macin","year":"2005","journal-title":"Am Heart J."},{"key":"10.4158\/EP171764.APPGL_bb2520","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastatto-Zocor Trial","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2525","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb2530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-147-1-200707030-00002","article-title":"Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease","volume":"147","author":"Wenger","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb2535","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.amjcard.2006.09.111","article-title":"Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study)","volume":"99","author":"Olsson","year":"2007","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2540","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.4158\/EP171764.APPGL_bb2545","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00041433-199612000-00008","article-title":"Statins: within-group comparisons, statin escape and combination therapy","volume":"7","author":"Tikkanen","year":"1996","journal-title":"Curr Opin Lipidol."},{"issue":"Suppl B","key":"10.4158\/EP171764.APPGL_bb2550","first-page":"28B","article-title":"Advances in drug treatment of dyslipidemia: focus on atorvastatin","volume":"14","author":"Davignon","year":"1998","journal-title":"Can J Cardiol"},{"key":"10.4158\/EP171764.APPGL_bb2555","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb2560","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/clc.4960240610","article-title":"Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia","volume":"24","author":"Davidson","year":"2001","journal-title":"Clin Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2565","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb2570","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia","volume":"110","author":"Knapp","year":"2001","journal-title":"Am J Med."},{"key":"10.4158\/EP171764.APPGL_bb2575","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.clinthera.2004.11.001","article-title":"Efficacy and safety of rosuvastatin alone and in combination with chole styramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial","volume":"26","author":"Ballantyne","year":"2004","journal-title":"Clin Ther."},{"key":"10.4158\/EP171764.APPGL_bb2580","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"Bays","year":"2004","journal-title":"Clin Ther."},{"key":"10.4158\/EP171764.APPGL_bb2585","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4065\/79.5.620","article-title":"Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial","volume":"79","author":"Goldberg","year":"2004","journal-title":"Mayo Clin Proc."},{"key":"10.4158\/EP171764.APPGL_bb2590","article-title":"Lescol (fluvastatin sodium) [prescribing information","year":"2012"},{"key":"10.4158\/EP171764.APPGL_bb2595","article-title":"Mevacor (lovastatin) [prescribing information]","year":"2014"},{"key":"10.4158\/EP171764.APPGL_bb2600","article-title":"Lipitor (atorvastatin calcium) [prescribing information].","year":"2015"},{"key":"10.4158\/EP171764.APPGL_bb2605","article-title":"Zocor (simvastatin) [prescribing information]","year":"2015"},{"key":"10.4158\/EP171764.APPGL_bb2610","article-title":"Crestor (rosuvastatin calcium) [prescribing information]","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb2615","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J."},{"key":"10.4158\/EP171764.APPGL_bb2620","year":"2011","journal-title":"NHLBI Communications Office. NIH stops clinical trial on combination cholesterol"},{"key":"10.4158\/EP171764.APPGL_bb2625","first-page":"25","article-title":"Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia","volume":"6","author":"Athyros","year":"1995","journal-title":"Coron Artery Dis."},{"key":"10.4158\/EP171764.APPGL_bb2630","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00001721-199509000-00007","article-title":"Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia","volume":"6","author":"Avellone","year":"1995","journal-title":"Blood Coagul Fibrinolysis."},{"key":"10.4158\/EP171764.APPGL_bb2635","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/01.ATV.16.4.511","article-title":"Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels","volume":"16","author":"Br\u00f6ijersen","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb2640","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-0038-1650548","article-title":"Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII","volume":"76","author":"Br\u00f6ijers\u00e9n","year":"1996","journal-title":"Thromb Haemost."},{"key":"10.4158\/EP171764.APPGL_bb2645","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1055\/s-0038-1657709","article-title":"Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients","volume":"78","author":"Kockx","year":"1997","journal-title":"Thromb Haemost."},{"key":"10.4158\/EP171764.APPGL_bb2650","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0021-9150(98)00003-3","article-title":"Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia","volume":"138","author":"Durrington","year":"1998","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb2655","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol","volume":"160","author":"Guyton","year":"2000","journal-title":"Niaspan-Gemfibrozil Study Group. Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb2660","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1053\/meta.2001.23308","article-title":"Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study","volume":"50","author":"Aguilar-Salinas","year":"2001","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb2665","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0149-2918(01)80102-8","article-title":"Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. (Erratum in: Clin Ther. 2001;23:1601)","volume":"23","author":"Bays","year":"2001","journal-title":"Clin Ther."},{"key":"10.4158\/EP171764.APPGL_bb2670","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)05271-5","article-title":"Effects of fenofibrate and gemfibrozil on plasma homocysteine","volume":"358","author":"Westphal","year":"2001","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb2675","first-page":"109","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. (Erratum in: Am J Cardiol. 2003;91:1399)","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2680","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagne","year":"2002","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2685","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron."},{"key":"10.4158\/EP171764.APPGL_bb2690","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4158\/EP.8.2.96","article-title":"Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study","volume":"8","author":"Insua","year":"2002","journal-title":"Endocr Pract."},{"key":"10.4158\/EP171764.APPGL_bb2695","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2003.10.003","article-title":"Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis","volume":"172","author":"Syv\u00e4nne","year":"2004","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb2700","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1185\/030079905X382004","article-title":"LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia","volume":"21","author":"Brohet","year":"2005","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP171764.APPGL_bb2705","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/eurheartj\/ehi231","article-title":"Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia","volume":"26","author":"Farnier","year":"2005","journal-title":"Eur Heart J."},{"key":"10.4158\/EP171764.APPGL_bb2710","first-page":"1035","volume":"22","author":"Bissonnette","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.4158\/EP171764.APPGL_bb2715","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3132\/dvdr.2006.020","article-title":"Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome","volume":"3","author":"Denke","year":"2006","journal-title":"Diab Vasc Dis Res."},{"key":"10.4158\/EP171764.APPGL_bb2720","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jacc.2005.11.072","article-title":"Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia","volume":"47","author":"McKenney","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2725","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2730","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clinthera.2007.01.003","article-title":"Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes","volume":"29","author":"Zieve","year":"2007","journal-title":"Clin Ther."},{"key":"10.4158\/EP171764.APPGL_bb2735","article-title":"Lopid (gemfibrozil) [prescribing information]","year":"2010"},{"key":"10.4158\/EP171764.APPGL_bb2740","article-title":"Tricor (fenofibrate) [prescribing information]","year":"2010"},{"key":"10.4158\/EP171764.APPGL_bb2745","article-title":"American Diabetes Association. Data from the 2011 National Diabetes Fact Sheet (released January 26, 2011)","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb2750","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb2755","article-title":"Juxtapid (lomitapide) [prescribing information]","year":"2012"},{"key":"10.4158\/EP171764.APPGL_bb2760","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1742-1241.2003.tb10508.x","article-title":"Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies","volume":"57","author":"Knopp","year":"2013","journal-title":"Int J Clin Pract."},{"key":"10.4158\/EP171764.APPGL_bb2765","article-title":"Livalo (pitavastatin) [prescribing information]","year":"2013"},{"key":"10.4158\/EP171764.APPGL_bb2770","article-title":"Zetia (ezetimibe) [prescribing information]","year":"2013"},{"key":"10.4158\/EP171764.APPGL_bb2775","article-title":"Colestid (colestipol hydrochloride) [prescribing information]","year":"2014"},{"key":"10.4158\/EP171764.APPGL_bb2780","article-title":"WelChol (colesevelam hydrochloride) [prescribing information]","year":"2014"},{"key":"10.4158\/EP171764.APPGL_bb2785","article-title":"Lovaza (omega-3-acid ethyl esters) [prescribing information]","year":"2015"},{"key":"10.4158\/EP171764.APPGL_bb2790","article-title":"Niaspan (niacin extended-release) [prescribing information]","year":"2015"},{"key":"10.4158\/EP171764.APPGL_bb2795","article-title":"Praluent (alirocumab) prescribing information","year":"2015"},{"key":"10.4158\/EP171764.APPGL_bb2800","article-title":"Prevalite (cholestyramine for oral suspension, USP) [prescribing information]","year":"2015"},{"key":"10.4158\/EP171764.APPGL_bb2805","article-title":"Kynamro (mipomersen sodium) Injection [prescribing information]","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb2810","article-title":"Pravachol (pravastatin sodium) [prescribing information]","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb2815","article-title":"Repatha (evolocumab) [prescribing information]","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb2820","article-title":"Trilipix (fenofibric acid) [prescribing information]","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb2825","article-title":"Vascepa (icosapent ethyl) [prescribing information]","year":"2016"},{"key":"10.4158\/EP171764.APPGL_bb2830","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","article-title":"Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors","volume":"32","author":"Lennern\u00e4s","year":"1997","journal-title":"Similarities and differences. Clin Pharmacokinet."},{"key":"10.4158\/EP171764.APPGL_bb2835","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0021-9150(02)00037-0","article-title":"Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux","volume":"163","author":"Guerin","year":"2002","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb2840","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1053\/meta.2002.30510","article-title":"Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose\/type 2 diabetes","volume":"51","author":"Pontrelli","year":"2002","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb2845","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1253\/circj.67.866","article-title":"Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients","volume":"67","author":"Sakabe","year":"2003","journal-title":"Circ J."},{"key":"10.4158\/EP171764.APPGL_bb2850","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/108155890405200333","article-title":"Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia","volume":"52","author":"van Tits","year":"2004","journal-title":"J Investig Med."},{"key":"10.4158\/EP171764.APPGL_bb2855","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijcard.2005.01.006","article-title":"Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin","volume":"104","author":"Baldassarre","year":"2005","journal-title":"Int J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2860","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/BF02849947","article-title":"Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes","volume":"22","author":"Bevilacqua","year":"2005","journal-title":"Adv Ther."},{"key":"10.4158\/EP171764.APPGL_bb2865","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.numecd.2004.08.001","article-title":"Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin","volume":"15","author":"Sirtori","year":"2005","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"10.4158\/EP171764.APPGL_bb2870","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1185\/030079906X80521","article-title":"The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study","volume":"22","author":"Miller","year":"2006","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP171764.APPGL_bb2875","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.4158\/EP171764.APPGL_bb2880","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study","volume":"357","author":"Ford","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2885","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). (Erratum in: Am J Cardiol. 1998;82:128)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2890","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2895","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.jacc.2008.11.002","article-title":"Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?","volume":"52","author":"Stein","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2900","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2905","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2910","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.4158\/EP171764.APPGL_bb2915","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper","year":"2007","journal-title":"Curr Opin Lipidol."},{"key":"10.4158\/EP171764.APPGL_bb2920","first-page":"493","article-title":"Simvastatin and side effects","volume":"104","author":"Scott","year":"1991","journal-title":"N Z Med J."},{"key":"10.4158\/EP171764.APPGL_bb2925","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1368-5031.2004.00278.x","article-title":"Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia","volume":"58","author":"Ballantyne","year":"2004","journal-title":"Int J Clin Pract."},{"key":"10.4158\/EP171764.APPGL_bb2930","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjcard.2004.06.049","article-title":"Safety of rosuvastatin","volume":"94","author":"Shepherd","year":"2004","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb2935","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clinthera.2005.02.011","article-title":"Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study","volume":"27","author":"Masana","year":"2005","journal-title":"Clin Ther."},{"key":"10.4158\/EP171764.APPGL_bb2940","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb2945","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00125-015-3528-5","article-title":"Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort","volume":"58","author":"Cederberg","year":"2015","journal-title":"Diabetologia."},{"key":"10.4158\/EP171764.APPGL_bb2950","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ."},{"key":"10.4158\/EP171764.APPGL_bb2955","first-page":"217","article-title":"Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study","volume":"59","author":"Jen","year":"1997","journal-title":"Zhonghua Yi Xue Za Zhi (Taipei)."},{"key":"10.4158\/EP171764.APPGL_bb2960","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2965","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.CIR.96.7.2137","article-title":"Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group","volume":"96","author":"Frick","year":"1997","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb2970","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/diacare.26.5.1513","article-title":"Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT)","volume":"26","author":"Robins","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb2975","first-page":"1563","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus. (Erratum in: N Engl J Med. 2010;362:1748)","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb2980","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/archinte.168.12.1333","article-title":"Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"168","author":"Folsom","year":"2008","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb2985","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(00)00474-3","article-title":"Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia","volume":"154","author":"Giral","year":"2001","journal-title":"Atherosclerosis."},{"key":"10.4158\/EP171764.APPGL_bb2990","doi-asserted-by":"crossref","first-page":"475","DOI":"10.33549\/physiolres.930856","article-title":"Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates","volume":"55","author":"Mayer","year":"2006","journal-title":"Physiol Res."},{"key":"10.4158\/EP171764.APPGL_bb2995","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2337\/diacare.28.6.1419","article-title":"Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia","volume":"28","author":"Koh","year":"2005","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb3000","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.metabol.2004.12.012","article-title":"The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia","volume":"54","author":"Saklamaz","year":"2005","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb3005","first-page":"158","article-title":"Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate","volume":"37","author":"Wu","year":"2007","journal-title":"Ann Clin Lab Sci."},{"key":"10.4158\/EP171764.APPGL_bb3010","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.164.7.697","article-title":"New perspectives on the use of niacin in the treatment of lipid disorders","volume":"164","author":"McKenney","year":"2004","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb3015","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7326\/0003-4819-139-12-200312160-00009","article-title":"Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia","volume":"139","author":"Meyers","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP171764.APPGL_bb3020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107424849600100302","article-title":"Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial","volume":"1","author":"Morgan","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"10.4158\/EP171764.APPGL_bb3025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb3030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1463-1326.2002.00205.x","article-title":"Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes","volume":"4","author":"Pan","year":"2002","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP171764.APPGL_bb3035","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/meta.2002.34701","article-title":"Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes","volume":"51","author":"Pan","year":"2002","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb3040","first-page":"1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial","volume":"284","author":"Elam","year":"2000","journal-title":"Arterial Disease Multiple Intervention Trial. JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3045","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb3050","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0197-2456(87)90156-5","article-title":"The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results","volume":"8","author":"Blankenhorn","year":"1987","journal-title":"Control Clin Trials."},{"key":"10.4158\/EP171764.APPGL_bb3055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb3060","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1001\/jama.1990.03450230049028","article-title":"Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up","volume":"264","author":"Cashin-Hemphill","year":"1990","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jacl.2007.05.003","article-title":"Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS)","volume":"1","author":"Vittone","year":"2007","journal-title":"J Clin Lipidol."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb3070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000174548","article-title":"Mechanism of action of bile acid sequestrants and other lipid-lowering drugs","volume":"76","author":"Shepherd","year":"1989","journal-title":"Cardiology."},{"key":"10.4158\/EP171764.APPGL_bb3075","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0026-0495(81)90140-2","article-title":"Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia","volume":"30","author":"Hunninghake","year":"1981","journal-title":"Metabolism."},{"key":"10.4158\/EP171764.APPGL_bb3080","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.CIR.69.2.313","article-title":"Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study","volume":"69","author":"Brensike","year":"1984","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb3085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9149(92)91264-5","article-title":"Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia","volume":"70","author":"Superko","year":"1992","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb3090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2125.1994.tb04239.x","article-title":"Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia","volume":"37","author":"Lyons","year":"1994","journal-title":"Br J Clin Pharmacol."},{"key":"10.4158\/EP171764.APPGL_bb3095","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb3100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.smj.0000208120.73327.db","article-title":"Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review","volume":"99","author":"Insull","year":"2006","journal-title":"South Med J."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb3105","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1007\/BF01409413","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications","volume":"40","author":"Probstfield","year":"1991","journal-title":"Eur J Clin Pharmacol."},{"key":"10.4158\/EP171764.APPGL_bb3110","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc08-0283","article-title":"Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy","volume":"31","author":"Fonseca","year":"2008","journal-title":"Diabetes Care."},{"key":"10.4158\/EP171764.APPGL_bb3115","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/archinte.168.18.1975","article-title":"Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects","volume":"168","author":"Bays","year":"2008","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb3120","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJM199504273321703","article-title":"Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?","volume":"332","author":"Andrade","year":"1995","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb3125","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.279.18.1458","article-title":"Persistence of use of lipid-lowering medications: a cross-national study","volume":"279","author":"Avorn","year":"1998","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4065\/76.10.971","article-title":"Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial","volume":"76","author":"Insull","year":"2001","journal-title":"Mayo Clin Proc."},{"key":"10.4158\/EP171764.APPGL_bb3135","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science."},{"key":"10.4158\/EP171764.APPGL_bb3140","first-page":"415","article-title":"Ezetimibe therapy: mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vasc Health Risk Manag."},{"key":"10.4158\/EP171764.APPGL_bb3145","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2362.2009.02163.x","article-title":"Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia","volume":"39","author":"Masuda","year":"2009","journal-title":"Eur J Clin Invest."},{"key":"10.4158\/EP171764.APPGL_bb3150","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1368-5031.2005.00565.x","article-title":"Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease","volume":"59","author":"Cruz-Fern\u00e1ndez","year":"2005","journal-title":"Int J Clin Pract."},{"key":"10.4158\/EP171764.APPGL_bb3155","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. (Erratum in: Am Heart J. 2005;149:882)","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J."},{"key":"10.4158\/EP171764.APPGL_bb3160","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients","volume":"22","author":"Catapano","year":"2006","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP171764.APPGL_bb3165","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ahj.2004.06.024","volume":"149","author":"Kastelein","year":"2005","journal-title":"Am Heart J."},{"key":"10.4158\/EP171764.APPGL_bb3170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1097-8690(08)70183-5","article-title":"Looking beyond the ezetimibe controversy","volume":"41","author":"Jellinger","year":"2008","journal-title":"Int Med News."},{"key":"10.4158\/EP171764.APPGL_bb3175","series-title":"Study to establish the clinical benefit\/safety of Vytorin (ezetimibe\/simvastatin tablet) vs simvastatin in subjects with acute coronary syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial -IMPROVE IT)","author":"Schering-Plough","year":"2007"},{"key":"10.4158\/EP171764.APPGL_bb3180","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb3185","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb3190","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12916-015-0503-4","article-title":"PCSK9 inhibition: the way forward in the treatment of dyslipidemia","volume":"13","author":"Stoekenbroek","year":"2015","journal-title":"BMC Med."},{"key":"10.4158\/EP171764.APPGL_bb3195","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J."},{"key":"10.4158\/EP171764.APPGL_bb3200","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J."},{"key":"10.4158\/EP171764.APPGL_bb3205","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1517\/17425255.2015.1075506","article-title":"PCSK9 inhibitors--past, present and future","volume":"11","author":"Reiner","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"10.4158\/EP171764.APPGL_bb3210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-5122(01)00302-4","article-title":"Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides","volume":"42","author":"Nerbrand","year":"2002","journal-title":"Maturitas."},{"key":"10.4158\/EP171764.APPGL_bb3215","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/13697130701877108","article-title":"Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents","volume":"11","author":"Dupuy","year":"2008","journal-title":"Climacteric."},{"key":"10.4158\/EP171764.APPGL_bb3220","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3225","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.288.1.49","article-title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3230","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","article-title":"North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society","volume":"19","year":"2012","journal-title":"Menopause."},{"key":"10.4158\/EP171764.APPGL_bb3235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/oxfordjournals.aje.a117239","article-title":"Effects of persistent physical activity and inactivity on coronary risk factors in children and young adults. The Cardiovascular Risk in Young Finns Study","volume":"140","author":"Raitakari","year":"1994","journal-title":"Am J Epidemiol."},{"key":"10.4158\/EP171764.APPGL_bb3240","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.281.2.180","article-title":"When should patients with heterozygous familial hypercholesterolemia be treated?","volume":"281","author":"Rifkind","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3245","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1172\/JCI116983","article-title":"Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level","volume":"93","author":"Sorensen","year":"1994","journal-title":"J Clin Invest."},{"key":"10.4158\/EP171764.APPGL_bb3250","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/01.ATV.16.8.984","article-title":"Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects","volume":"16","author":"Tonstad","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP171764.APPGL_bb3255","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0009-9120(96)00167-1","article-title":"Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis","volume":"30","author":"Hegele","year":"1997","journal-title":"Clin Biochem."},{"key":"10.4158\/EP171764.APPGL_bb3260","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1542\/peds.96.2.239","article-title":"Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population","volume":"96","author":"Assouline","year":"1995","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb3265","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1161\/CIRCULATIONAHA.106.179568","volume":"114","author":"Kavey","year":"2006","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb3270","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jama.292.3.377","article-title":"Targeting high-risk young patients for statin therapy","volume":"292","author":"Gotto","year":"2004","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3275","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(92)92092-T","article-title":"Simvastatin use in children","volume":"339","author":"Ducobu","year":"1992","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb3280","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0140-6736(92)91745-T","article-title":"Treatment of hypercholesterolaemia in children","volume":"340","author":"Sinzinger","year":"1992","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb3285","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(94)90094-9","article-title":"Sleep disturbance and appetite loss after lovastatin","volume":"343","author":"Sinzinger","year":"1994","journal-title":"Lancet."},{"key":"10.4158\/EP171764.APPGL_bb3290","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1203\/00006450-199605000-00021","article-title":"Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia","volume":"39","author":"Knipscheer","year":"1996","journal-title":"Pediatr Res."},{"key":"10.4158\/EP171764.APPGL_bb3295","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1542\/peds.97.5.619","article-title":"Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group","volume":"97","author":"Lambert","year":"1996","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb3300","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.281.2.137","article-title":"Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial","volume":"281","author":"Stein","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3305","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00431-003-1181-3","article-title":"The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation","volume":"162","author":"Dirisamer","year":"2003","journal-title":"Eur J Pediatr."},{"key":"10.4158\/EP171764.APPGL_bb3310","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3476(03)00186-0","article-title":"Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multi-center, randomized, placebo-controlled trial","volume":"143","author":"McCrindle","year":"2003","journal-title":"J Pediatr."},{"key":"10.4158\/EP171764.APPGL_bb3315","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3320","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-3476(96)70188-9","article-title":"Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia","volume":"129","author":"Tonstad","year":"1996","journal-title":"J Pediatr."},{"key":"10.4158\/EP171764.APPGL_bb3325","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/adc.74.2.157","article-title":"Low dose colestipol in adolescents with familial hypercholesterolaemia","volume":"74","author":"Tonstad","year":"1996","journal-title":"Arch Dis Child."},{"key":"10.4158\/EP171764.APPGL_bb3330","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-3476(05)83444-4","article-title":"Use of cholestyramine in the treatment of children with familial combined hyperlipidemia","volume":"122","author":"Liacouras","year":"1993","journal-title":"J Pediatr."},{"key":"10.4158\/EP171764.APPGL_bb3335","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000116766.31036.03","article-title":"Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia","volume":"109","author":"Salen","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb3340","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1542\/peds.92.1.78","article-title":"Niacin treatment of hypercholesterolemia in children","volume":"92","author":"Colletti","year":"1993","journal-title":"Pediatrics."},{"key":"10.4158\/EP171764.APPGL_bb3345","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/01.CIR.0000033222.75187.B9","article-title":"Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women","volume":"106","author":"Blake","year":"2002","journal-title":"Circulation."},{"key":"10.4158\/EP171764.APPGL_bb3350","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1194\/jlr.M300395-JLR200","article-title":"Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis","volume":"45","author":"Witte","year":"2004","journal-title":"J Lipid Res."},{"key":"10.4158\/EP171764.APPGL_bb3355","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1373\/clinchem.2005.059949","article-title":"Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics","volume":"52","author":"Ensign","year":"2006","journal-title":"Clin Chem."},{"key":"10.4158\/EP171764.APPGL_bb3360","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/ AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb3365","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med."},{"key":"10.4158\/EP171764.APPGL_bb3370","doi-asserted-by":"crossref","first-page":"147","DOI":"10.7326\/0003-4819-113-2-147","article-title":"A clinician\u2019s guide to cost-effectiveness analysis","volume":"113","author":"Detsky","year":"1990","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb3375","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.hjr.0000216550.74258.12","article-title":"Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach","volume":"14","author":"Martikainen","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"10.4158\/EP171764.APPGL_bb3380","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0002-8223(01)00250-4","article-title":"Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled trial","volume":"101","author":"Delahanty","year":"2001","journal-title":"J Am Diet Assoc."},{"key":"10.4158\/EP171764.APPGL_bb3385","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0002-8223(00)00066-3","article-title":"Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance","volume":"100","author":"Sikand","year":"2000","journal-title":"J Am Diet Assoc."},{"key":"10.4158\/EP171764.APPGL_bb3390","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2307\/3342753","article-title":"The costs of smoking and the cost effectiveness of smoking-cessation programs","volume":"11","author":"Elixhauser","year":"1990","journal-title":"J Public Health Policy."},{"key":"10.4158\/EP171764.APPGL_bb3395","doi-asserted-by":"crossref","first-page":"22G","DOI":"10.1016\/S0002-9149(03)00229-7","article-title":"How cost-effective are new preventive strategies for cardiovascular disease?","volume":"91","author":"Probstfield","year":"2003","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb3400","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S0266462307051598","article-title":"Primary prevention of cardiovascular disease: cost-effectiveness comparison","volume":"23","author":"Franco","year":"2007","journal-title":"Int J Technol Assess Health Care."},{"key":"10.4158\/EP171764.APPGL_bb3405","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/00019053-200826060-00004","article-title":"Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers","volume":"26","author":"Howard","year":"2008","journal-title":"Pharmacoeconomics."},{"issue":"Suppl 1","key":"10.4158\/EP171764.APPGL_bb3410","doi-asserted-by":"crossref","first-page":"i53","DOI":"10.1136\/tc.2006.019794","article-title":"The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline","volume":"16","author":"Hollis","year":"2007","journal-title":"Tob Control."},{"key":"10.4158\/EP171764.APPGL_bb3415","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00019053-200725120-00005","article-title":"Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events","volume":"25","author":"Plosker","year":"2007","journal-title":"Pharmacoeconomics."},{"key":"10.4158\/EP171764.APPGL_bb3420","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1524-4733.2008.00354.x","article-title":"Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications","volume":"11","author":"Ohsfeldt","year":"2008","journal-title":"Value Health."},{"key":"10.4158\/EP171764.APPGL_bb3425","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M14-1430","article-title":"Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States","volume":"162","author":"Odden","year":"2015","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb3430","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA."},{"key":"10.4158\/EP171764.APPGL_bb3435","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/clc.22535","article-title":"Cost-Effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States","volume":"39","author":"Gandra","year":"2016","journal-title":"Clin Cardiol."},{"key":"10.4158\/EP171764.APPGL_bb3440","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00019053-200523020-00005","article-title":"Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease","volume":"23","author":"Hay","year":"2005","journal-title":"Pharmacoeconomics."},{"key":"10.4158\/EP171764.APPGL_bb3445","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archinte.162.2.177","article-title":"Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial","volume":"162","author":"Nyman","year":"2002","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP171764.APPGL_bb3450","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00019053-200624080-00007","article-title":"Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada","volume":"24","author":"Kohli","year":"2006","journal-title":"Pharmacoeconomics."},{"issue":"iii","key":"10.4158\/EP171764.APPGL_bb3455","first-page":"xi","article-title":"Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation","volume":"12","author":"Ara","year":"2008","journal-title":"Health Technol Assess"},{"key":"10.4158\/EP171764.APPGL_bb3460","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.ajkd.2015.09.020","article-title":"Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)","volume":"67","author":"Mihaylova","year":"2016","journal-title":"Am J Kidney Dis."},{"key":"10.4158\/EP171764.APPGL_bb3465","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0149-2918(00)88308-3","article-title":"A population-based treat-to-target pharmaco-economic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia","volume":"21","author":"Hilleman","year":"1999","journal-title":"Clin Ther."},{"key":"10.4158\/EP171764.APPGL_bb3470","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00129784-200606030-00005","article-title":"Cost-effectiveness analysis of cholesterol-lowering therapies in Spain","volume":"6","author":"Plans-Rubio","year":"2006","journal-title":"Am J Cardiovasc Drugs."},{"key":"10.4158\/EP171764.APPGL_bb3475","first-page":"251","article-title":"Cost-effectiveness analysis of simvastatin and lovastatin\/ extended-release niacin to achieve LDL and HDL goal using NHANES data","volume":"10","author":"Armstrong","year":"2004","journal-title":"J Manag Care Pharm."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20429593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20429593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:04:08Z","timestamp":1761516248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20429593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":686,"alternative-id":["S1530891X20429593"],"URL":"https:\/\/doi.org\/10.4158\/ep171764.appgl","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP171764.APPGL","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}